

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SS\$PTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 3 JUL 28 EPFULL enhanced with additional legal status
information from the EPOline Register
NEWS 4 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5 JUL 28 STN Viewer performance improved
NEWS 6 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 8 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 9 AUG 15 CAPLUS currency for Korean patents enhanced
NEWS 10 AUG 27 CAS definition of basic patents expanded to ensure
comprehensive access to substance and sequence
information
NEWS 11 SEP 18 Support for STN Express, Versions 6.01 and earlier,
to be discontinued
NEWS 12 SEP 25 CA/CAPLUS current-awareness alert options enhanced
to accommodate supplemental CAS indexing of
exemplified prophetic substances
NEWS 13 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and
and Korean patents enhanced
NEWS 14 SEP 29 IFICLS enhanced with new super search field
NEWS 15 SEP 29 EMBASE and EMBAL enhanced with new search and
display fields
NEWS 16 SEP 30 CAS patent coverage enhanced to include exemplified
prophetic substances identified in new Japanese-
language patents
NEWS 17 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 18 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 19 OCT 22 Current-awareness alert (SDI) setup and editing
enhanced
NEWS 20 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 21 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:09:02 ON 14 NOV 2008

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:09:17 ON 14 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 NOV 2008 HIGHEST RN 1072687-23-0

DICTIONARY FILE UPDATES: 13 NOV 2008 HIGHEST RN 1072687-23-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

10594024

=>

Uploading C:\Program Files\Stnexp\Queries\10594024.str



```
chain nodes :
18 19 20 21 22 23 24 25 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
1-19 5-20 8-21 14-27 17-18 18-19 18-24 19-22 20-21 20-23 21-25
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17
exact/norm bonds :
1-2 1-5 1-19 8-21 14-27 17-18 18-19 19-22 20-21 20-23
exact bonds :
2-3 3-4 4-5 5-20 18-24 21-25
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 6 : 12 :
```

G1:O,X

Match level :

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS
```


10594024

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,X

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:09:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 77 TO ITERATE

100.0% PROCESSED 77 ITERATIONS

42 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1014 TO 2066

PROJECTED ANSWERS: 452 TO 1228

L2 42 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 09:09:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1458 TO ITERATE

100.0% PROCESSED 1458 ITERATIONS



649 ANSWERS

SEARCH TIME: 00.00.01

L3 649 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10594024a.str



```

chain nodes :
18 19 20 21 22 23 24 25 27 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
1-19 5-20 8-21 14-27 17-18 18-19 18-24 19-22 20-21 20-23 21-25
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17
exact/norm bonds :
1-2 1-5 1-19 8-21 14-27 17-18 18-19 19-22 20-21 20-23
exact bonds :
2-3 3-4 4-5 5-20 18-24 21-25
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 6 : 12 :
```

G1:O,X

G2:A,Cy,Hy

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS 30:CLASS
31:Atom
```


L4 STRUCTURE UPLOADED

10594024

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 O,X

G2 A,Cy,Ry

Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 09:11:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 76 TO ITERATE

100.0% PROCESSED 76 ITERATIONS

42 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 997 TO 2043

PROJECTED ANSWERS: 451 TO 1227

L5 42 SEA SSS SAM L4

=> s 14 sss full

FULL SEARCH INITIATED 09:12:02 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1416 TO ITERATE

100.0% PROCESSED 1416 ITERATIONS

646 ANSWERS

SEARCH TIME: 00.00.01

L6 646 SEA SSS FUL L4

=> FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

358.10

358.31

FILE 'HCAPLUS' ENTERED AT 09:12:18 ON 14 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 13 Nov 2008 (20081113/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L7 17 L3



=> s l6
L8 17 L6

=> s l8 and py<=2004
25113662 PY<=2004
L9 6 L8 AND PY<=2004

=> d l9 ibib abs hitstr tot

L9 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857591 HCAPLUS
DOCUMENT NUMBER: 141:314626
TITLE: Method for the production of
pyrrolidine-1,2-dicarboxylic
acid-1-(phenyl(-amide))-2-(phenyl(-amide)) derivatives
and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid
derivatives as intermediate products
INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch,
Dieter; Cezanne, Bertram; Gleitz, Johannes
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315377	A1	20041014	DE 2003-10315377	20030403 <--
DE 10327428	A1	20050105	DE 2003-10327428	20030618
DE 10329295	A1	20050203	DE 2003-10329295	20030630
DE 10329457	A1	20050120	DE 2003-10329457	20030701
DE 10334174	A1	20050217	DE 2003-10334174	20030726
AU 2004226280	A1	20041014	AU 2004-226280	20040309 <--
CA 2520893	A1	20041014	CA 2004-2520893	20040309 <--
EP 1608646	A1	20051228	EP 2004-718646	20040309
EP 1608646	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008888	A	20060411	BR 2004-8888	20040309
JP 2006522037	T	20060928	JP 2006-504602	20040309
EP 1760081	A1	20070307	EP 2006-22891	20040309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
US 20060211692	A1	20060921	US 2005-551670	20050930
IN 2005KN02182	A	20060929	IN 2005-KN2182	20051103
PRIORITY APPLN. INFO.:			DE 2003-10315377	A 20030403
			DE 2003-10327428	A 20030618
			DE 2003-10329295	A 20030630
			DE 2003-10329457	A 20030701
			DE 2003-10334174	A 20030726
			EP 2004-718646	A3 20040309
			WO 2004-EP2405	W 20040309
OTHER SOURCE(S):		CASREACT 141:314626; MARPAT 141:314626		
GI				



AB The invention relates to a method for the production of title compds., e.g. (I), and intermediate products, e.g. (II) for the production of I. Thus, cis-hydroxy-D-proline was reacted with 4-chlorophenylisocyanate in NaHCO_3 at 80° for 5 h. to give after workup 81.8% (R,R)-II. II was then reacted with 4-(3-oxo-4-morpholinyl)aniline in THF with 2-ethoxy-1(2H)-quinolinecarboxylic acid Et ester (EEDQ) as coupling agent at room temperature for 20 h to give, after workup, 69% (R,R)-I.

IT 768370-75-8P 768370-91-8P 768370-94-1P
768370-99-6P 768371-04-6P 768371-10-4P
768371-14-8P 768371-19-3P 768371-23-9P
768371-27-3P 768371-31-9P 768371-35-3P
768371-38-6P 768371-42-2P 768371-48-8P
768371-51-3P 768371-54-6P 768371-59-1P
768371-65-9P 768371-67-1P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of substituted Ph 1,2-pyrrolidinedicarboxylic acid diamides and intermediates)

RN 768370-75-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-91-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-94-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-99-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-04-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-10-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-14-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-19-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-23-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-31-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-35-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-38-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-42-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-(acetyloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-48-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-oxo-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-51-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-54-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-59-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-65-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-67-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857551 HCAPLUS

DOCUMENT NUMBER: 141:350179

TITLE: Preparation of azolidinedicarboxamides and related compounds as Factor Xa and Factor VIIa inhibitors
Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308 <--
WO 2004087646	A3	20050106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


DE 10315377	A1	20041014	DE 2003-10315377	20030403 <--
DE 10329295	A1	20050203	DE 2003-10329295	20030630
AU 2004226278	A1	20041014	AU 2004-226278	20040308 <--
CA 2521069	A1	20041014	CA 2004-2521069	20040308 <--
BR 2004008420	A	20060321	BR 2004-8420	20040308
JP 2006522033	T	20060928	JP 2006-504581	20040308
EP 1720844	A2	20061115	EP 2004-718299	20040308

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV
 RU 2337099 C2 20081027 RU 2005-133870 20040308
 IN 2005KN01684 A 20070727 IN 2005-KN1684 20050823
 US 20060183739 A1 20060817 US 2005-551557 20051003

PRIORITY APPLN. INFO.:

DE 2003-10315377	A	20030403
DE 2003-10329295	A	20030630
US 2003-483897P	P	20030702
WO 2004-EP2350	W	20040308

OTHER SOURCE(S): MARPAT 141:350179
 GI



AB R1R2(TYX)EWCOGD [R1, R2 = H, O, halo, A, ethynyl, OR3, N(R3)2, NO2, cyano, N3, CO2R3, CON(R3)2, etc.; R3 = H, A, HC.tplbond.CCH2, MeC.tplbond.CCH2, CH2CH(OH)CH2OH, etc.; R4 = H, A; W = N, C, CR3; E = atoms to form a 3-7 membered (heterocyclic) ring optionally containing a double bond; D = mono- or dinuclear (substituted) (hetero)aryl; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS, etc.; n = 0-2; X = [C(R4)2]nCO[C(R4)2]n, [C(R4)2]nNR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, heterocyclylene, arenediyl; T = substituted mono- or dinuclear carbocyclyl, heterocyclyl; A = (fluoro-substituted) alkyl optionally interrupted by O, S, CH:CH], were prepared Thus, title compound (I) [preparation from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate given] bound to Factor Xa receptors with IC50 = 1.8 + 10⁻⁸ M.

IT 536747-22-5P 536748-46-6P 768370-75-8P 768370-91-8P 768370-94-1P 768370-99-6P 768371-04-6P 768371-10-4P 768371-14-8P 768371-19-3P 768371-23-9P 768371-27-3P 768371-31-9P 768371-35-3P 768371-38-6P 768371-42-2P 768371-48-8P 768371-51-3P

768371-59-1P 768371-65-9P 768371-67-1P
 773888-70-3P 773888-71-4P 773889-01-3P
 773889-02-4P 773889-03-5P 773889-04-6P
 773889-05-7P 773889-06-8P 773889-07-9P
 773889-08-0P 773889-09-1P 773889-10-4P
 773889-11-5P 773889-12-6P 773889-13-7P
 773889-14-8P 773889-15-9P 773889-16-0P
 773889-17-1P 773889-27-3P 774601-40-0P
 774601-41-1P 774601-42-2P 774601-45-5P
 774601-46-6P 774601-47-7P 774601-48-8P
 774601-51-3P 774601-52-4P 774601-53-5P
 774601-54-6P 774601-55-7P 774601-56-8P
 774601-57-9P 774601-58-0P 774601-61-5P
 774601-62-6P 774601-73-9P 774601-74-0P
 774601-75-1P 774601-76-2P 774601-77-3P
 774601-78-4P 774601-79-5P 774601-84-2P
 774601-85-3P 774601-86-4P 774601-87-5P
 774601-88-6P 774601-89-7P 774601-90-0P
 774601-91-1P 774601-92-2P 774601-93-3P
 774601-94-4P 774601-96-6P 774601-97-7P
 774601-98-8P 774601-99-9P 774602-00-5P
 774602-48-1P 774602-49-2P 774602-50-5P
 774602-51-6P 774602-52-7P 774602-53-8P
 774602-54-9P 774602-55-0P 774602-58-3P
 774602-59-4P 774602-60-7P 774602-61-8P
 774602-73-2P 774602-74-3P 774602-75-4P
 774602-79-8P 775347-83-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolidinedicarboxamides and related compds. as Factor Xa and Factor VIIa inhibitors)

RN 536747-22-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-46-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-75-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-91-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-94-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-99-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-04-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-10-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-14-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-19-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-23-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-31-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-35-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-38-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-42-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetyloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-48-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-oxo-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-51-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-59-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-65-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-67-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773888-70-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773888-71-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-01-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-dimethoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-02-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-03-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-04-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-05-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R,3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-06-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 773889-07-9 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3,4-dihydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 773889-08-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-09-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)

morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-10-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-11-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-12-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

[(methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-13-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-14-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-15-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-propoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-16-0 HCAPLUS

CN Propanoic acid, 2-methyl-, (3R,5R)-1-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-5-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-17-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(1-oxopropoxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-40-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetamino)-N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-41-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-[(butylsulfonyl)amino]-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-42-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-45-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-46-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-47-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-48-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(2-methyl-1-

oxopropyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-51-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-52-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-53-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(2-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-54-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-55-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-56-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-57-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-58-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-61-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-62-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-73-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-74-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-75-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(2-butyne-1-yloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-76-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-(2,3-dihydroxypropoxy)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-77-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[2-hydroxy-3-(1-pyrrolidinyl)propoxy]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-78-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-[(2-oxo-5-oxazolidinyl)methoxy]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-79-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(3-amino-2-hydroxypropoxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-84-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-85-3 HCAPLUS

CN Benzoic acid, 2-[[[(2R,3R)-1-[[4-(4-chlorophenyl)amino]carbonyl]-3-hydroxy-2-pyrrolidinyl]carbonyl]amino]-5-(3-oxo-4-morpholinyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-86-4 HCAPLUS

CN Benzoic acid, 2-[[[(2R,3R)-1-[[4-(4-chlorophenyl)amino]carbonyl]-3-hydroxy-2-pyrrolidinyl]carbonyl]amino]-5-(3-oxo-4-morpholinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-87-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3,4-dihydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,3S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-88-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-89-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-90-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propyn-1-yloxy)-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-91-1 HCAPLUS

CN Acetic acid, 2-[[[(3R,5R)-1-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl]oxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-92-2 HCAPLUS

CN Acetic acid, 2-[[[(3R,5R)-1-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 774601-93-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-bromophenyl)-N2-[2-fluoro-4-(3-oxo-4-

morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-94-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-(2,3-dihydroxypropoxy)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-96-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-97-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-imino-1-pyrrolidinyl)-3-methylphenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774601-98-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-imino-5-methyl-3(2H)-thiazolyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774601-99-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-(aminocarbonyl)-4-(3-oxo-4-morpholinyl)phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-00-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-2-methyl-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-48-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(tetrahydro-5-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-49-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(tetrahydro-5-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-50-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2S)-2-methyl-3-oxo-4-morpholinyl]phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 774602-51-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2S)-2-methyl-3-

oxo-4-morpholinyl]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-52-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2R)-2-methyl-3-oxo-4-morpholinyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-53-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2R)-2-methyl-3-oxo-4-morpholinyl]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-54-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-2-phenoxyphenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-55-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2R)-2-methyl-3-oxo-4-morpholinyl]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774602-58-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-(2-methoxyethoxy)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-59-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(tetrahydro-3-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-60-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-methyl-4-(tetrahydro-3-oxo-1,4-oxazepin-4(5H)-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-61-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-73-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[2-(dimethylamino)ethoxy]-4-morpholinyl]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 774602-74-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-ethoxy-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-75-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-propoxy-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 774602-79-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 775347-83-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2E)-2-(cyanoimino)-1-imidazolidinyl]phenyl]-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)




IT 773889-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azolidinedicarboxamides and related compds. as Factor Xa and Factor VIIa inhibitors)

RN 773889-50-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-[(4-nitrobenzoyl)oxy]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:841766 HCAPLUS

DOCUMENT NUMBER: 141:332202

TITLE: Preparation of azolidinecarboxamides as antithrombotics and anticancer drugs.

INVENTOR(S): Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Ger. Offen., 47 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10315377	A1	20041014	DE 2003-10315377	20030403 <--
AU 2004226278	A1	20041014	AU 2004-226278	20040308 <--
CA 2521069	A1	20041014	CA 2004-2521069	20040308 <--
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308 <--
WO 2004087646	A3	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004008420	A	20060321	BR 2004-8420	20040308


CN 1771237	A	20060510	CN 2004-80009354	20040308
JP 2006522033	T	20060928	JP 2006-504581	20040308
EP 1720844	A2	20061115	EP 2004-718299	20040308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
RU 2337099	C2	20081027	RU 2005-133870	20040308
AU 2004226280	A1	20041014	AU 2004-226280	20040309 <--
AU 2004226281	A1	20041014	AU 2004-226281	20040309 <--
CA 2520893	A1	20041014	CA 2004-2520893	20040309 <--
CA 2520894	A1	20041014	CA 2004-2520894	20040309 <--
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004087696	A1	20041014	WO 2004-EP2407	20040309 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1608645	A1	20051228	EP 2004-718641	20040309
EP 1608645	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
EP 1608646	A1	20051228	EP 2004-718646	20040309
EP 1608646	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008444	A	20060404	BR 2004-8444	20040309
BR 2004008888	A	20060411	BR 2004-8888	20040309
CN 1771248	A	20060510	CN 2004-80009374	20040309
CN 1771249	A	20060510	CN 2004-80009463	20040309
JP 2006522037	T	20060928	JP 2006-504602	20040309
JP 2006522038	T	20060928	JP 2006-504604	20040309
AT 361296	T	20070515	AT 2004-718641	20040309
AT 366732	T	20070815	AT 2004-718646	20040309
ES 2285444	T3	20071116	ES 2004-718641	20040309
ES 2287708	T3	20071216	ES 2004-718646	20040309
IN 2005KN01684	A	20070727	IN 2005-KN1684	20050823
US 20060211692	A1	20060921	US 2005-551670	20050930
US 20060183739	A1	20060817	US 2005-551557	20051003
US 20060183742	A1	20060817	US 2005-551559	20051003
IN 2005KN02182	A	20060929	IN 2005-KN2182	20051103

IN 2005KN02183
PRIORITY APPLN. INFO.:

A 20070323

IN 2005-KN2183 20051103
DE 2003-10315377 A 20030403
DE 2003-10327428 A 20030618
DE 2003-10329295 A 20030630
DE 2003-10329457 A 20030701
US 2003-483897P P 20030702
DE 2003-10334174 A 20030726
DE 2003-10336570 A 20030808
WO 2004-EP2350 W 20040308
WO 2004-EP2405 W 20040309
WO 2004-EP2407 W 20040309

OTHER SOURCE(S): MARPAT 141:332202
GI



AB R1R2(TYX)EWCODG [R1, R2 = H, O, halo, A, ethynyl, OR3, NO2, cyano, N3, CO2R3, CON(R3)2, NR3COA, NR3SO2A, etc.; R1R2 = toms to form a bicyclic or spirocyclic (heterocyclic) ring; R3 = H, A, etc.; R4 = H, A; W = N, CR3, C; E = atoms to form a 3-7 membered (double bond containing) (heterocyclic) ring with W; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS; X = [C(R4)2]nCONR3[C(R4)2]n, [C(R4)2]nON[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, (substituted) heterocyclylene, arylyne; T = mono- or bicyclic substituted (unsatd.) (hetero)cyclyl; A = (fluoro-substituted) alkylene optionally interrupted by O, S, CH:CH; n = 0-2], were prepared Thus, title compound (I) (prepared from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate), bound to Factor Xa receptors with IC50 = 1.8 + 10-8 M.

IT 768370-75-8P 768370-91-8P 768370-94-1P
768370-99-6P 768371-04-6P 768371-10-4P
768371-14-8P 768371-19-3P 768371-23-9P
768371-27-3P 768371-31-9P 768371-35-3P
768371-38-6P 768371-42-2P 768371-65-9P
773888-70-3P 773888-71-4P 773889-01-3P
773889-02-4P 773889-03-5P 773889-04-6P
773889-05-7P 773889-06-8P 773889-07-9P
773889-08-0P 773889-09-1P 773889-10-4P
773889-11-5P 773889-12-6P 773889-13-7P
773889-14-8P 773889-15-9P 773889-16-0P
773889-17-1P 773889-27-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of azolidinecarboxamides as antithrombotics

and


anticancer drugs)

RN 768370-75-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-

morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-91-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-94-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768370-99-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-04-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-10-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-14-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-19-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-23-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)-3-(trifluoromethyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-31-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-35-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-38-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-42-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-(acetyloxy)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 768371-65-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propen-1-yloxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773888-70-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773888-71-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-01-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-02-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-03-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-04-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-05-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R,3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-06-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-3-hydroxy-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 773889-07-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-3,4-dihydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 773889-08-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)

morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-09-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-10-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-11-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[4-(3-

oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-12-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-13-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(methylsulfonyl)amino]-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-14-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-15-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-propoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 773889-16-0 HCAPLUS

CN Propanoic acid, 2-methyl-, (3R,5R)-1-[[4-(4-chlorophenyl)amino]carbonyl]-5-

[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-17-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(1-oxopropoxy)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 773889-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethynyl-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 773889-50-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of azolidinecarboxamides as antithrombotics and anticancer
drugs)

RN 773889-50-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-[(4-nitrobenzoyl)oxy]-
N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:799558 HCAPLUS

DOCUMENT NUMBER: 141:296012

TITLE: Preparation of factor Xa- and thrombin-inhibiting
substituted benzamides and sulfonylbenzamides as
potential anticoagulants

INVENTOR(S): Pinto, Donald J.; Qiao, Jennifer X.; Gangor, Timur;
Lam, Patrick Y. S.; Li, Yun-long

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 279 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083174	A2	20040930	WO 2004-US8033	20040317 <--
WO 2004083174	A3	20041125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040209863	A1	20041021	US 2004-801518	20040316 <--
US 7122557	B2	20061017		
EP 1603562	A2	20051214	EP 2004-757516	20040317
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			US 2003-455709P	P 20030318
			US 2004-801518	A 20040316
			WO 2004-US8033	W 20040317

OTHER SOURCE(S): MARPAT 141:296012
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. P4-M-M4 (I) [M = (un)substituted 3-10 membered carbocyclic or a 4-10 membered heterocyclic ring containing 1-3 O, N, or S atoms, alone or fused to an (un)substituted 5-7 membered carbocycle or heterocycle; P4 = Z-A-B; M4 = G-G1; A = (un)substituted 3-10 membered carbocyclic or 5-12 membered heterocyclic ring; B = (un)substituted amidino, guanidino, iminomethyl; G = five or six-membered carbocycle or heterocycle fused to a benzene, pyridine, pyrimidine, pyrazine, or pyridazine ring; G1 = bond, (un)substituted alkyl, alkenyl, alkynyl; Z = (un)substituted alkylene], such as tetrahydropyrazolo[3,4-c]pyridinone II or (pyridinylaminocarbonylphenylaminocarbonyl)benzamide III are prepared as inhibitors of Factor Xa and thrombin for use as anticoagulants. Deprotection of 2-amino-4-chloropyridine and addition to 5-chloroisatoic anhydride yields N-(5-chloro-2-pyridinyl) 2-amino-5-chlorobenzamide (IV). Acid-mediated addition of dimethylamine to the nitrile of Me 4-cyanobenzoate, mesylation of the amidine nitrogen, and base-mediated hydrolysis of the ester yields 4-(N,N-dimethyl-N'-methylsulfonylamidino)benzoic acid (V). Coupling of IV and V mediated by BOP yields III. Some compds. of the invention inhibit human factor Xa with Ki values of $\leq 10 \mu\text{M}$; in addition, some of the invention compds. inhibit thrombin in vitro. (no data).

IT 764658-81-3P 764658-82-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(preparation of factor Xa- and thrombin-inhibiting substituted benzamides
and sulfonylbenzamides as potential anticoagulants)

RN 764658-81-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(E)-
[(methylsulfonyl)imino]-1-pyrrolidinylmethyl]phenyl]-, (2R)- (CA INDEX
NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 764658-82-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-
[(dimethylamino)[(methylsulfonyl)imino]methyl]phenyl]-, (2R)- (CA INDEX
NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L9 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2003:434528 HCAPLUS

DOCUMENT NUMBER: 139:6763

TITLE: Preparation of pyrrolidinedicarboxamides and related
compounds as inhibitors of factor Xa useful for

thrombotic disorders
 INVENTOR(S): Bigge, Christopher Franklin; Dudley, Danette Andrea;
 Edmunds, Jeremy John; Van Huis, Chad Alan;
 Casimiro-Garcia, Agustin; Filipski, Kevin James;
 Kohrt, Jeffrey Thomas
 PATENT ASSIGNEE(S): Warner-Lambert Company L.L.C., USA
 SOURCE: PCT Int. Appl., 389 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045912	A1	20030605	WO 2002-IB4757	20021114 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030162787	A1	20030828	US 2002-278643	20021023 <--
US 7030141	B2	20060418		
CA 2468715	A1	20030605	CA 2002-2468715	20021114 <--
AU 2002365313	A1	20030610	AU 2002-365313	20021114 <--
AU 2002365313	B2	20080306		
BR 2002014519	A	20041013	BR 2002-14519	20021114 <--
EP 1465864	A1	20041013	EP 2002-803885	20021114 <--
EP 1465864	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1582274	A	20050216	CN 2002-823837	20021114
HU 2004002529	A2	20050329	HU 2004-2529	20021114
JP 2005515985	T	20050602	JP 2003-547364	20021114
AT 320414	T	20060415	AT 2002-803885	20021114
EP 1671949	A2	20060621	EP 2006-110738	20021114
EP 1671949	A3	20060719		
EP 1671949	B1	20080723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PT 1465864	T	20060630	PT 2002-803885	20021114
ES 2259113	T3	20060916	ES 2002-803885	20021114
NZ 532384	A	20061027	NZ 2002-532384	20021114
AP 1744	A	20070630	AP 2004-3035	20021114
AT 402148	T	20080815	AT 2006-110738	20021114
MX 2004PA03606	A	20040727	MX 2004-PA3606	20040416 <--
ZA 2004004085	A	20050905	ZA 2004-4085	20040525
NO 2004002270	A	20040601	NO 2004-2270	20040601 <--
US 20050267118	A1	20051201	US 2004-17598	20041220
US 7407972	B2	20080805		
US 20050250815	A1	20051110	US 2005-108582	20050418
US 7407974	B2	20080805		

US 20060264626
PRIORITY APPLN. INFO.:

A1 20061123

US 2006-461859		20060802
US 2001-334168P	P	20011122
US 2002-384895P	P	20020531
US 2002-278643	A3	20021023
EP 2002-803885	A3	20021114
WO 2002-IB33416	A	20021114
WO 2002-IB4757	W	20021114
US 2004-17598	A3	20041220

OTHER SOURCE(S) : MARPAT 139:6763
GI




AB The present invention provides pyrrolidinedicarboxamides and related compds. (shown as I; variables defined below; e.g.
(R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]) and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compns. comprising ≥ 1 compds. I, processes for preparing I, and intermediates useful for preparing I. IC50 values for inhibition of factor Xa are tabulated for >170 examples of I. About 180 example preps. of I are included. For example,
(R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] was prepared in 4 steps starting from Fmoc-D-Pro, SOCl2, and 4-bromo-2-fluoroaniline and involving intermediates (R)-2-[(4-bromo-2-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylic acid 9H-fluorene-9-ylmethyl ester, (R)-pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide, and (R)-pyrrolidine-1,2-dicarboxylic acid
2-[(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide]
1-[(4-chlorophenyl)amide] with yields of 99, 70, 66 and 76%, resp. Four pharmaceutical formulations are described. For I: A is (un)substituted aryl or (un)substituted monocyclic heteroaryl; B is -NHC(O)(C1-C6)alkyl, -NHC(O)(C3-C7)cycloalkyl, -NHC(O)O(C1-C6)alkyl, -C(O)R1, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4-C7)cycloalkenyl, unsatd. (C4-C7)heterocyclo, aryl, or heteroaryl, any of which may be (un)substituted by halo, (C1-C6)alkyl, or halo(C1-C6)alkyl, O(C1-C6), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido. C is Ph or heteroaryl, wherein Ph or heteroaryl is (un)substituted with ≥ 2 substituents = aryl, heteroaryl, halogen, hydroxy, -CO2R2, -COR2, -CONR2R2', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; G is H, halo, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, -CH2O(C1-C6)alkyl, -CH2CO2(C1-C6)alkyl, -CH2NR2R2', or -CH2C(O)NH(C1-C6)alkyl. W1 is a saturated or unsatd., (un)substituted hydrocarbon chain or hydrocarbon-heteroatom chain having 2-6 atoms, wherein W1 connects the N atom at position 1 to the C atom at position 2 to form a four to eight membered ring; R1 is (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4-C7)cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -NR3R4; R2 and


R2' are each independently H or (C1-C6)alkyl; and R3 and R4 are each independently H, (C1-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxy carbonyl, aralkoxy carbonyl, -SO₂alkyl, or joined together to form a saturated or unsatd. 3 to 7 membered ring.

IT 536746-63-1P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536746-77-7P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(4-cyanophenyl)amide]
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)
 RN 536746-63-1 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536746-77-7 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-(4-cyanophenyl)- (CA INDEX NAME)



IT 536746-25-5P, (R)-Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]
 536746-29-9P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]
 536746-36-8P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(2,4-difluorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536746-38-0P, Pyrrolidine-1,2-dicarboxylic acid
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-methoxyphenyl)amide]
 536746-39-1P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-bromophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]
 536746-42-6P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(3,4-difluorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536746-49-3P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536746-60-8P, Pyrrolidine-1,2-dicarboxylic acid
 2-[(3-chloro-2'-methanesulfonylbiphenyl-4-yl)amide]
 1-[(4-chlorophenyl)amide] 536746-74-4P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]amide]
 536746-75-5P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]amide] trifluoroacetate 536746-78-8P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(2'-methanesulfonylbiphenyl-4-yl)amide] 536746-82-4P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(2'-methanesulfonyl-3-methylbiphenyl-4-yl)amide] 536746-87-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536746-88-0P, (2R)-4-Oxopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536746-89-1P, (2R,4S)-4-Fluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536746-91-5P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide]
 1-[(4-fluorophenyl)amide] 536746-93-7P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(2'-methanesulfonyl-3-trifluoromethylbiphenyl-4-yl)amide]
 536746-98-2P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-05-4P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2-oxopiperidin-1-yl)phenyl]amide]
 536747-06-5P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-10-1P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-11-2P, (2R,4R)-4-Propoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-13-4P, (2R,4R)-4-Cyanopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-14-5P, (2R,4R)-4-Fluoropyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-15-6P,

(2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxoazetidin-1-yl)phenyl]amide]
 536747-17-8P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]amide] 536747-19-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxoazepan-1-yl)phenyl]amide]
 536747-22-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]amide] 536747-23-6P,
 (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-1,2-dihydropyridin-1-yl)phenyl]amide] 536747-25-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2S)-2-hydroxymethyl-5-oxopyrrolidin-1-yl)phenyl]amide] 536747-26-9P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,3-dimethyl-5-oxo-2,5-dihydropyrazol-1-yl)phenyl]amide] 536747-27-0P,
 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(2-hydroxymethylpyrrolidin-1-yl)phenyl]amide] 536747-28-1P
 , (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrrolidin-1-yl)phenyl]amide]
 536747-29-2P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrazol-1-yl)phenyl]amide]
 536747-30-5P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrazol-1-yl)phenyl]amide]
 536747-31-6P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-[1,2,4]triazol-1-ylphenyl]amide]
 536747-32-7P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-[1,2,3]triazol-2-ylphenyl]amide]
 536747-33-8P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-[1,2,3]triazol-1-ylphenyl]amide]
 536747-34-9P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(acetylamino)phenyl]amide] 1-[(4-chlorophenyl)amide]
 536747-35-0P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-[(cyclopentanecarbonyl)amino]phenyl]amide]
 536747-36-1P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-pyrimidin-5-ylphenyl]amide]
 536747-37-2P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrazol-1-yl)phenyl]amide]
 536747-38-3P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrazol-1-yl)phenyl]amide]
 536747-39-4P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrazol-1-yl)phenyl]amide]
 536747-40-7P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrazol-1-yl)phenyl]amide]
 536747-41-8P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methylpyrazol-1-yl)phenyl]amide] 536747-46-3P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methylpyrazol-1-yl)phenyl]amide] 536747-47-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methylpyrazol-1-yl)phenyl]amide] 536747-48-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

1-[(4-chlorophenyl)amide] 2-[[4-(5-methylpyrazol-1-yl)phenyl]amide]
 536747-49-6P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethylpyrazol-1-yl)phenyl]amide]
 536747-50-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethylpyrazol-1-yl)phenyl]amide]
 536747-51-0P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethylpyrazol-1-yl)-2-fluorophenyl]amide] 536747-53-2P,
 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(4-tert-butylphenyl)amide]
 1-[(4-chlorophenyl)amide] 536747-54-3P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-61-2P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(2,3-dimethyl-5-oxo-2,5-dihydropyrazol-1-yl)phenyl]amide]
 536747-68-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-oxo-6H-pyridazin-1-yl)phenyl]amide] 536747-70-3P,
 (2R,4S)-4-Aminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-73-6P,
 (2R,4R)-4-Aminopyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-75-8P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-76-9P,
 (2R)-4-Hydroxyiminopyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-77-0P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methylsulfamoylbiphenyl-4-yl)amide] 536747-78-1P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-dimethylsulfamoyl-3-fluorobiphenyl-4-yl)amide] 536747-80-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-82-7P,
 (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-83-8P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536747-84-9P,
 (2R,4S)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-85-0P, (2R,4R)-4-Fluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-86-1P,
 (2R)-4,4-Difluoropyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-88-3P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide]
 1-[(4-fluorophenyl)amide] 536747-89-4P,
 (2R,4R)-4-Acetylamino pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-90-7P, (2R,4R)-4-Methanesulfonylaminopyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536747-91-8P, (2R,4S)-4-(1H-Tetrazol-5-yl)pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]

2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-92-9P,
 (2R,4S)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-93-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-methylimidazol-1-yl)phenyl]amide] 536747-94-1P,
 (2R,4R)-4-(1H-Tetrazol-5-yl)pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-95-2P,
 (2R,4R)-4-Trifluoromethylpyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536747-96-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-cyano-3-fluorobiphenyl-4-yl)amide] 536747-97-4P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[(2'-aminomethyl-3-fluorobiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536747-98-5P, (2R,4R)-4'-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3'-fluorobiphenyl-2-carboxylic acid methyl ester 536747-99-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,5-dihydropyrrole-1-carbonyl)phenyl]amide] 536748-04-6P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(4-dimethylcarbamoyl-2-fluorophenyl)amide] 536748-09-1P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrrolidine-1-carbonyl)phenyl]amide] 536748-10-4P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrrolidine-1-carbonyl)phenyl]amide] 536748-11-5P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2-methylpyrrolidine-1-carbonyl)phenyl]amide] 536748-12-6P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(ethylmethyl)carbamoyl]phenyl]amide] 536748-13-7P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(4-dimethylcarbamoyl)phenyl]amide] 536748-14-8P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2R-methylpyrrolidine-1-carbonyl)phenyl]amide] 536748-15-9P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2S-methylpyrrolidine-1-carbonyl)phenyl]amide] 536748-16-0P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrrolidine-1-carbonyl)phenyl]amide] 536748-17-1P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrrolidine-1-carbonyl)-2-(pyrrolidin-1-yl)phenyl]amide] 536748-18-2P,
 (2R,4R)-4'-[[1-[(4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-(pyrrolidin-1-yl)benzoic acid methyl ester 536748-19-3P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(azetidine-1-carbonyl)phenyl]amide] 1-[(4-chlorophenyl)amide] 536748-23-9P, (2R,4R)-4'-[[1-[(4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-dimethylaminobenzoic acid methyl ester 536748-24-0P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(pyrrolidine-1-carbonyl)phenyl]amide] 536748-25-1P,

(2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(4-dimethylcarbamoylphenyl)amide]
 536748-26-2P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrrolidine-1-carbonyl)phenyl]amide]
 536748-27-3P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(4-dimethylcarbamoylphenyl)amide]
 536748-28-4P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrrolidine-1-carbonyl)phenyl]amide] 536748-29-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(4-dimethylcarbamoyl-2-fluorophenyl)amide]
 536748-30-8P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrrolidine-1-carbonyl)phenyl]amide] 536748-31-9P,
 (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(4-dimethylcarbamoyl-2-fluorophenyl)amide]
 536748-32-0P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-methyl-4-(2-oxopiperidin-1-yl)phenyl]amide] 536748-33-1P,
 (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-methyl-4-(2-oxopiperidin-1-yl)phenyl]amide] 536748-34-2P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-quinolin-8-ylphenyl]amide]
 536748-35-3P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[3,5-difluoro-2'-methanesulfonylbiphenyl-4-yl]amide]
 536748-36-4P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-2-methylbiphenyl-4-yl)amide] 536748-37-5P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonylbiphenyl-4-yl)amide] 536748-38-6P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonylbiphenyl-4-yl)amide]
 536748-39-7P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-methyl-2'-methylsulfonylbiphenyl-4-yl)amide]
 536748-40-0P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-41-1P,
 (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3-methylbiphenyl-4-yl)amide]
 536748-42-2P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3-trifluoromethylbiphenyl-4-yl)amide]
 536748-43-3P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-methoxybiphenyl-4-yl)amide]
 536748-44-4P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(2'-hydroxybiphenyl-4-yl)amide]
 536748-45-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-iodophenyl]amide]
 536748-46-6P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-48-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-hydroxy-2-oxopiperidin-1-yl)phenyl]amide] 536748-49-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxotetrahydropyrimidin-1-yl)phenyl]amide] 536748-50-2P,

(2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxoimidazolidin-1-yl)phenyl]amide] 536748-51-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxooxazolidin-3-yl)phenyl]amide] 536748-52-4P,
 (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxopiperidine-3-carboxylic acid ethyl ester 536748-53-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-55-7P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3-methyl-2-oxo-1H-pyridin-1-yl)phenyl]amide] 536748-59-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(4-(morpholin-4-yl)phenyl)amide] 536748-60-4P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(2-methyl-5-oxopyrrolidin-1-yl)phenyl]amide] 536748-62-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-64-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-67-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-69-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-71-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536748-72-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(5-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536748-89-7P,
 Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(1H-tetrazol-5-yl)phenyl]amide] 536748-90-0P,
 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-91-1P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-92-2P,
 4-Oxopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-93-3P,
 4-Methylenepyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-94-4P,
 4-Methylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-95-5P,
 4,4-Difluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-96-6P,
 4-Aminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-97-7P,
 4-Hydroxymethylpyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-98-8P, 1-[(4-Chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidine-3-carboxylic

acid 536748-99-9P, 1-[(4-Chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidine-3-carboxylic acid methyl ester 536749-00-5P, Pyrrolidine-1,2,4-tricarboxylic acid 4-amide 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-01-6P, 4-Aminomethylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-02-7P, 4-Methoxymethylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-03-8P, 4-Ethoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-04-9P, 4-Methylaminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-05-0P, 4-Acetylamino pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-06-1P, 4-Methanesulfonylaminopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-07-2P, 5-Oxopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-12-9P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3-methylbiphenyl-4-yl)amide] 536749-13-0P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonylbiphenyl-4-yl)amide] 536749-16-5P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3-trifluoromethylbiphenyl-4-yl)amide] 536749-21-0P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-ethyl-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-22-1P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-ethyl-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-23-2P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5-difluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-24-3P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5-dichloro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-25-4P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5-dichloro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-26-5P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3,5-dimethylbiphenyl-4-yl)amide] 536749-27-6P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-3,5-dimethylbiphenyl-4-yl)amide] 536749-28-7P, Pyrrolidine-1,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl-5-methylbiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536749-29-8P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl-5-methylbiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536749-30-1P, Pyrrolidine-1,2-dicarboxylic acid 2-[(2-chloro-2'-methanesulfonylbiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536749-31-2P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(2-chloro-2'-methanesulfonylbiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536749-32-3P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2'-methanesulfonyl-2-methylbiphenyl-4-yl)amide] 536749-33-4P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-34-5P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(2-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-35-6P

, 4-[[1-[(4-Chlorophenyl)carbamoyl]pyrrolidine-2-carbonyl]amino]-2'-methanesulfonylbiphenyl-3-carboxylic acid methyl ester
536749-36-7P, 4-[[1-[(4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-2'-methanesulfonylbiphenyl-3-carboxylic acid methyl ester 536749-41-4P,
Pyrrolidine-1,2-dicarboxylic acid 1-[(3-chloro-4-fluorophenyl)amide]
2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-44-7P,
Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-2-methylphenyl)amide]
2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-45-8P,
Pyrrolidine-1,2-dicarboxylic acid 1-[(3,4-dichlorophenyl)amide]
2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-48-1P,
(2S)-Pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-49-2P,
4-Hydroxypyrrolidine-1,2-dicarboxylic acid
2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide]
1-[(4-fluorophenyl)amide] 536749-52-7P,
4-Fluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-53-8P,
(2R,4S)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid
1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536749-54-9P, 1-[(4-Chlorophenyl)carbamoyl]-5-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyl]pyrrolidine-3-carboxylic acid 536749-55-0P, 1-[(4-Chlorophenyl)carbamoyl]-5-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyl]pyrrolidine-3-carboxylic acid methyl ester 536749-56-1P, 1-[(4-Chlorophenyl)carbamoyl]-5-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyl]pyrrolidine-3-carboxylic acid ethyl ester 536749-57-2P, Pyrrolidine-1,2,4-tricarboxylic acid 4-amide 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-58-3P,
4-Cyanopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-59-4P,
4-(1H-Tetrazol-5-yl)pyrrolidine-1,2-dicarboxylic acid
1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-60-7P,
4-Aminomethylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-61-8P,
4-Methylaminomethylpyrrolidine-1,2-dicarboxylic acid
1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-62-9P,
4-Dimethylaminomethylpyrrolidine-1,2-dicarboxylic acid
1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-63-0P,
4-Acetylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide]


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536746-25-5 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536746-29-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)




RN 536746-36-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(2,4-difluorophenyl)- (CA INDEX NAME)




RN 536746-38-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-methoxyphenyl)- (CA INDEX NAME)




RN 536746-39-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-bromophenyl)- (CA INDEX NAME)




RN 536746-42-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3,4-dibromophenyl)- (CA INDEX NAME)




RN 536746-49-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536746-60-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[3-chloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)



RN 536746-74-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 536746-75-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 536746-74-4

CMF C22 H24 Cl N5 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10594024


RN 536746-78-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536746-82-4 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536746-87-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536746-88-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-oxo-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536746-89-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536746-91-5 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-fluorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536746-93-7 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536746-98-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-05-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-06-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-10-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-11-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-propoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-13-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-cyano-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-14-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-15-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-17-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-pyrrolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-19-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(hexahydro-2-oxo-1H-azepin-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-22-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-23-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-25-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2S)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-26-9 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536747-27-0 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[2-(hydroxymethyl)-1-pyrrolidinyl]phenyl]- (CA INDEX NAME)



RN 536747-28-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1-pyrrolidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-29-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536747-30-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-31-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-32-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(2H-1,2,3-triazol-2-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-33-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1H-

1,2,3-triazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-34-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-(acetylamino)phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-35-0 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(cyclopentylcarbonyl)amino]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536747-36-1 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(5-pyrimidinyl)phenyl]- (CA INDEX NAME)



RN 536747-37-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-38-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-39-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-

(1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-40-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-41-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-46-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-1H-pyrazol-1-yl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-47-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-48-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-49-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-1H-

pyrazol-1-yl)phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-50-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-51-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-1H-pyrazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



10594024

RN 536747-53-2 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(1,1-dimethylethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 536747-54-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3,5'-difluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-61-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-68-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo-1(6H)-pyridazinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-70-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-73-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-75-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536747-76-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(hydroxyimino)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 536747-77-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-
[(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 536747-78-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-
[(dimethylamino)sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-4-hydroxy-,
(2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-80-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-82-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-83-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-ethoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-84-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-85-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-86-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-88-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-fluorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-89-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-(acetylmino)-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-90-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl) [1,1'-biphenyl]-4-yl]-4-[(methylsulfonyl)amino]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-91-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(2H-tetrazol-5-yl)-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-92-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-93-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-methyl-1H-imidazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-94-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(2H-tetrazol-5-yl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-95-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(trifluoromethyl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-96-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-(2'-cyano-3-fluoro[1,1'-biphenyl]-4-yl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-97-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[2'-(aminomethyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536747-98-5 HCAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid,
4'-[[[(2R,4R)-1-[[[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-
pyrrolidinyl]carbonyl]amino]-3'-fluoro-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-99-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2,5-dihydro-1H-
pyrrol-1-yl)carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-04-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-
[(dimethylamino)carbonyl]-2-fluorophenyl]-4-hydroxy-, (2R,4R)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 536748-09-1 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536748-10-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]- (CA INDEX NAME)




RN 536748-11-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(2-pyrrolidinylcarbonyl)amino]phenyl]- (CA INDEX NAME)

methyl-1-pyrrolidinyl)carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-12-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[(propylamino)carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-13-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-14-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-15-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[4-[[[(2S)-2-methyl-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-16-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-pyrrolidinyl)carbonyl]phenyl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-17-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-(1-pyrrolidinyl)-4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-18-2 HCAPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[[[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-3-(1-pyrrolidinyl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-19-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-(1-azetidiny carbonyl)phenyl]-N1-(4-chlorophenyl)-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-23-9 HCAPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[[4-(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidiny]carbonyl]amino]-3-(dimethylamino)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-24-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-25-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-26-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536748-27-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-
[(dimethylamino)carbonyl]phenyl]-4-ethoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-28-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-
pyrrolidinylcarbonyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-29-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-
[(dimethylamino)carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 536748-30-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-fluoro-4-(1-pyrrolidinylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-31-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(dimethylamino)carbonyl]-2-fluorophenyl]-4-ethoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-32-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[2-methyl-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-33-1 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-methyl-4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-34-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(8-quinolinyl)phenyl]- (CA INDEX NAME)



RN 536748-35-3 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-difluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536748-36-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


10594024



RN 536748-37-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-38-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-39-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-2'-(methylthio)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-40-0 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-41-1 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536748-42-2 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-43-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-(2'-methoxy[1,1'-biphenyl]-4-yl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-44-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-(2'-hydroxy[1,1'-biphenyl]-4-yl)-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-45-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-(2-fluoro-4-iodophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-46-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-48-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-

hydroxy-2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-49-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-2-oxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-50-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536748-51-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-52-4 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2-oxo-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-53-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-55-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-59-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(4-morpholinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-60-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(2-methyl-5-oxo-1-pyrrolidinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-62-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-64-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536748-67-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-69-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-71-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-72-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536748-89-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)




RN 536748-90-0 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)



RN 536748-91-1 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy- (CA INDEX NAME)




RN 536748-92-2 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-oxo- (CA INDEX NAME)




RN 536748-93-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methylene- (CA INDEX NAME)




RN 536748-94-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methyl- (CA INDEX NAME)




RN 536748-95-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536748-96-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-amino-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536748-97-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(hydroxymethyl)- (CA INDEX NAME)




RN 536748-98-8 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[4-chlorophenyl]amino]carbonyl]-5-[[[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]- (CA INDEX NAME)




RN 536748-99-9 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 536749-00-5 HCAPLUS

CN 1,2,4-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-01-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(aminomethyl)-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-02-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methoxymethyl)- (CA INDEX NAME)




RN 536749-03-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-04-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methylamino)- (CA INDEX NAME)




RN 536749-05-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(acetylamino)-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-06-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-[(methylsulfonyl)amino]- (CA INDEX NAME)




RN 536749-07-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-5-oxo- (CA INDEX NAME)




RN 536749-12-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[3-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-13-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-18-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2'-(methylsulfonyl)-3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-21-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-ethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-22-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-ethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-23-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-diethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-24-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dichloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-25-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dichloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-26-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dimethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-27-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[3,5-dimethyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-28-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[3-chloro-5-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)




RN 536749-29-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-chloro-5-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)




RN 536749-30-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-chloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)- (CA INDEX NAME)




RN 536749-31-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-chloro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)




RN 536749-32-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-hydroxy-N2-[2-methyl-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-33-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 536749-34-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536749-35-6 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
 4-[[[1-[(4-chlorophenyl)amino]carbonyl]-2-pyrrolidinyl]carbonyl]amino]-2'-
 (methylsulfonyl)-, methyl ester (CA INDEX NAME)




RN 536749-36-7 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid,
 4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-
 pyrrolidinyl]carbonyl]amino]-2'-(methylsulfonyl)-, methyl ester (CA INDEX
 NAME)




RN 536749-41-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)




RN 536749-44-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chloro-2-methylphenyl)- (CA INDEX NAME)



RN 536749-45-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3,4-dichlorophenyl)- (CA INDEX NAME)



RN 536749-48-1 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536749-49-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 536749-52-7 HCAPLUS


CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536749-53-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536749-54-9 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[4-(2-fluoro-4-(2-oxo-1-piperidinyl)phenyl)amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]- (CA INDEX NAME)




RN 536749-55-0 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)




RN 536749-56-1 HCAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-[[[(4-chlorophenyl)amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 536749-57-2 HCAPLUS

CN 1,2,4-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-58-3 HCAPLUS

CN 1,2-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-4-cyano-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-59-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 536749-60-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-(aminomethyl)-N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-61-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-[(methylamino)methyl]- (CA INDEX NAME)




RN 536749-62-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-[(dimethylamino)methyl]-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 536749-63-0 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, 4-acetyl-N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



IT 536749-64-1P, Pyrrolidine-1,2,4-tricarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 4-methylamide 536749-65-2P,
 Pyrrolidine-1,2,4-tricarboxylic acid 1-[(4-chlorophenyl)amide]
 4-dimethylamide 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide]
 536749-66-3P, 4-Trifluoromethylpyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-67-4P,
 4-Methylpyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-68-5P,
 4-Isopropoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-69-6P,
 4-Fluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-70-9P,
 4,4-Difluoropyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]

2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536749-71-0P,
 1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]phenyl]pyrrolidine-2-carboxylic acid 536749-72-1P
 , 1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]phenyl]pyrrolidine-2-carboxylic acid 536749-88-9P
 , 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-hydroxymethyl-5-oxopyrrolidin-1-yl)phenyl]amide]
 536749-89-0P, 1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-5-oxopyrrolidine-2-carboxylic acid 536749-90-3P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-fluorophenyl]amide]
 536749-91-4P, 1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2,5-dioxoimidazolidin-4-yl]acetic acid 536749-92-5P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(5,5-dimethyl-2,4-dioxooxazolidin-3-yl)-2-fluorophenyl]amide]
 536749-93-6P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,5-dioxopyrrolidin-1-yl)-2-fluorophenyl]amide] 536749-94-7P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-oxooxazolidin-3-yl)phenyl]amide] 536749-95-8P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(2,5-dioxooxazolidin-3-yl)-2-fluorophenyl]amide]
 536749-96-9P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxoimidazolidin-1-yl)phenyl]amide] 536749-97-0P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(2,5-dioxoimidazolidin-1-yl)-2-fluorophenyl]amide]
 536749-98-1P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2,5-dioxoimidazolidin-1-yl)phenyl]amide] 536749-99-2P,
 3-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxoimidazolidine-4-carboxylic acid
 536750-00-2P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2,4,5-trioxoimidazolidin-1-yl)phenyl]amide] 536750-01-3P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(2,5-dioxo-2,5-dihydropyrrol-1-yl)-2-fluorophenyl]amide]
 536750-02-4P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(2-aminomethyl-5-oxopyrrolidin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536750-03-5P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(2-carbamoyl-5-oxopyrrolidin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536750-04-6P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(2,2-bis(hydroxymethyl)-5-oxopyrrolidin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536750-05-7P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(3,3-dimethyl-2,5-dioxopyrrolidin-1-yl)-2-fluorophenyl]amide]
 536750-06-8P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3,3,4-trimethyl-2,5-dioxopyrrolidin-1-yl)phenyl]amide] 536750-07-9P,
 1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-5-oxopyrrolidine-2,2-dicarboxylic acid
 536750-08-0P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-methyl-5-oxopyrrolidin-1-

yl)phenyl]amide] 536750-09-1P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-methyl-6-oxopiperidin-1-yl)phenyl]amide]
 536750-10-4P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-hydroxy-2-oxopiperidin-1-yl)phenyl]amide] 536750-11-5P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(5-methyl-2,6-dioxotetrahydropyrimidin-1-yl)phenyl]amide]
 536750-12-6P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxotetrahydropyrimidin-1-yl)phenyl]amide] 536750-13-7P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-1-yl)phenyl]amide]
 536750-14-8P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,5-dioxopiperazin-1-yl)-2-fluorophenyl]amide] 536750-15-9P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(3-hydroxy-2-oxo-2H-pyridin-1-yl)phenyl]amide]
 536750-16-0P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536750-17-1P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(6-methyl-2-oxo-4-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536750-18-2P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[4-(2,6-dioxopiperidin-1-yl)-2-fluorophenyl]amide] 536750-19-3P,
 1-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxopiperidine-3-carboxylic acid
 536750-20-6P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(5,5-dihydroxy-2,4,6-trioxotetrahydropyrimidin-1-yl)-2-fluorophenyl]amide] 536750-21-7P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2,4,6-trioxotetrahydropyrimidin-1-yl)phenyl]amide]
 536750-22-8P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)-2-fluorophenyl]amide] 536750-23-9P,
 4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide]
 2-[[2-fluoro-4-(2-hydroxy-4-oxoazetidin-1-yl)phenyl]amide]
 536750-24-0P, 4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(acetyl-methylamino)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide]
 536750-25-1P, 4-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-1H-pyrrole-3-carboxylic acid 536750-26-2P,
 2-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2H-pyrazole-3-carboxylic acid
 536750-27-3P, 1-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-1H-imidazole-2-carboxylic acid 536750-28-4P,
 1-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-1H-pyrrole-2-carboxylic acid
 536750-29-5P, 3-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-1H-pyrrole-2-carboxylic acid 536750-30-8P,
 3-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]furan-2-carboxylic acid
 536750-31-9P, 3-[[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]thiophene-2-carboxylic

acid 536750-32-0P, 4-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxyppyrrolidine-2-carbonyl]amino]-3-fluorophenyl]furan-3-carboxylic acid 536750-33-1P, 4-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxyppyrrolidine-2-carbonyl]amino]-3-fluorophenyl]thiophene-3-carboxylic acid 536750-42-2P, 4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(5'-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536750-43-3P, 4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536750-44-4P, 4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(5'-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536750-45-5P, 4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536750-47-7P, 4-Hydroxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536750-48-8P, 4-Hydroxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3,5'-difluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536750-51-3P, 4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(2,3-dimethyl-5-oxo-2,5-dihydropyrazol-1-yl)phenyl]amide] 536750-55-7P, 4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-oxo-6H-pyridazin-1-yl)phenyl]amide] 536750-56-8P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-methyl-5-oxo-5H-[1,2,4]triazin-4-yl)phenyl]amide] 536750-57-9P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 2-[[4-(3-chloro-5-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536750-58-0P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3-methyl-5-oxo-4,5-dihydropyrazol-1-yl)phenyl]amide] 536750-59-1P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 2-[[4-(5-chloro-3-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536750-60-4P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethoxy-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536750-61-5P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methoxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536750-62-6P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-(pyrrol-1-yl)-2H-pyridin-1-yl)phenyl]amide] 536750-63-7P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-phenyl-2H-pyridin-1-yl)phenyl]amide] 536750-65-9P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2-oxopyrrolidin-1-yl)phenyl]amide] 536750-66-0P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2-oxoimidazolidin-1-yl)phenyl]amide] 536750-67-1P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dimethyl-2-oxoimidazolidin-1-yl)-2-fluorophenyl]amide] 536750-68-2P, (2R,4R)-4-Methoxyppyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3,5,5-trimethyl-2-

oxoimidazolidin-1-yl)phenyl]amide] 536750-69-3P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-isopropyl-5,5-dimethyl-2-oxoimidazolidin-1-yl)phenyl]amide] 536750-70-6P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methyl-2-oxoimidazolidin-1-yl)phenyl]amide] 536750-71-7P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(5,5-dimethyl-2-oxoimidazolidin-1-yl)-2-fluorophenyl]amide] 536750-72-8P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3,4-dimethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536750-73-9P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(4-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536750-83-1P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-quinolin-1-yl)phenyl]amide] 536750-84-2P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-oxo-3H-isoquinolin-2-yl)phenyl]amide] 536750-85-3P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(1-oxo-1H-isoquinolin-2-yl)phenyl]amide] 536750-86-4P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-oxo-5H-[1,2,4]triazin-4-yl)phenyl]amide] 536750-87-5P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-oxo-6H-pyrimidin-1-yl)phenyl]amide] 536750-88-6P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyrazin-1-yl)phenyl]amide] 536750-89-7P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyrimidin-1-yl)phenyl]amide] 536750-90-0P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-[1,3,5]triazin-1-yl)phenyl]amide] 536750-92-2P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]amide] 536750-93-3P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(1-methyl-1H-pyrrol-2-yl)phenyl]amide] 536750-95-5P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridine-1-carbonyl)phenyl]amide] 536750-96-6P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-3H-imidazol-4-yl)phenyl]amide] 536750-97-7P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-methyl-2H-pyrazol-3-yl)phenyl]amide] 536750-99-9P,
 (2R, 4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-5-oxo-2,5-

dihydropyrazol-1-yl)phenyl]amide] 536751-00-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methoxymethyl-3-methylpyrazol-1-yl)phenyl]amide] 536751-01-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methoxymethyl-5-methylpyrazol-1-yl)phenyl]amide] 536751-02-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-ethyl-3-methylpyrazol-1-yl)phenyl]amide] 536751-03-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-isobutyl-3-methylpyrazol-1-yl)phenyl]amide] 536751-04-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-isopropylpyrazol-1-yl)phenyl]amide] 536751-05-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-ethylpyrazol-1-yl)phenyl]amide] 536751-06-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-isobutylpyrazol-1-yl)phenyl]amide] 536751-07-2P,
 (2R,4R)-2-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2H-pyrazole-3-carboxylic acid methyl ester 536751-08-3P, (2R,4R)-2-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2H-pyrazole-3-carboxylic acid 536751-09-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methoxymethylpyrazol-1-yl)phenyl]amide] 536751-10-7P,
 (2R,4R)-5-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]oxazole-4-carboxylic acid ethyl ester 536751-11-8P, (2R,4R)-5-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]oxazole-4-carboxylic acid ethyl ester 536751-12-9P,
 (2R,4R)-5-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]oxazole-4-carboxylic acid 536751-13-0P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methoxymethylloxazol-5-yl)phenyl]amide] 536751-14-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(4-ethyloxazol-5-yl)-2-fluorophenyl]amide] 536751-15-2P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-isopropylloxazol-5-yl)phenyl]amide] 536751-22-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methylisoxazol-3-yl)phenyl]amide] 536751-23-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(4-methylisoxazol-3-yl)phenyl]amide] 536751-24-3P, (2R,4R)-3-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]isoxazole-4-carboxylic acid methyl ester 536751-25-4P,
 (2R,4R)-3-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]isoxazole-4-carboxylic acid 536751-26-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(4-methoxymethylisoxazol-3-

yl)phenyl]amide] 536751-27-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-isopropylisoxazol-3-yl)phenyl]amide] 536751-28-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-cyclopropylisoxazol-3-yl)phenyl]amide] 536751-29-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(4-cyclopropylisoxazol-3-yl)phenyl]amide] 536751-31-2P, (2R,4R)-4-Ethoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-methyl-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-45-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(ethylisopropyl)carbamoyl]phenyl]amide] 536751-46-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(ethylisopropyl)carbamoyl]-2-fluorophenyl]amide] 536751-47-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3-ethylpyrrolidine-1-carbonyl)phenyl]amide] 536751-48-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3-ethylpyrrolidine-1-carbonyl)-2-fluorophenyl]amide] 536751-49-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3R-aminopyrrolidine-1-carbonyl)phenyl]amide] 1-[(4-chlorophenyl)amide] 536751-50-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3R-aminopyrrolidine-1-carbonyl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536751-51-6P
 , (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3S-aminopyrrolidine-1-carbonyl)phenyl]amide] 1-[(4-chlorophenyl)amide] 536751-52-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3S-aminopyrrolidine-1-carbonyl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536751-53-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3R-methylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-54-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3R-methylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-55-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3S-methylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-56-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3S-methylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-57-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3R-ethylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-58-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3R-ethylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-59-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3S-ethylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-60-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3S-ethylaminopyrrolidine-1-carbonyl)phenyl]amide] 536751-62-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,5-dihydropyrrole-1-carbonyl)-2-fluorophenyl]amide] 536751-64-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(pyrrole-1-carbonyl)phenyl]amide] 536751-65-2P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(pyrrole-1-carbonyl)phenyl]amide] 536751-68-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-fluoro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-69-6P,
 (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-3-carboxylic acid 536751-70-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-hydroxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-71-0P,
 (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid 536751-72-1P, (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-2-carboxylic acid methyl ester 536751-73-2P,
 (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]phenyl]-2,5-dioximidazolidin-4-yl]acetic acid 536751-74-3P, (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid methyl ester 536751-75-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536751-76-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-hydroxy-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-77-6P,
 (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-2-carboxylic acid 536751-78-7P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536751-79-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(6-cyclopropyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536751-80-1P,
 (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-6-oxo-1,6-dihydropyridine-3-carboxylic acid ethyl ester 536751-81-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3,3-dimethyl-2-oxoazetidin-1-yl)phenyl]amide] 536751-82-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(7-oxo-7H-thieno[2,3-c]pyridin-6-yl)phenyl]amide] 536751-83-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-1-azaspiro[4.5]dec-1-yl)phenyl]amide] 536751-84-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-benzoyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536751-85-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid


2-[[4-(3-acetylsulfamoyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536751-86-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxothiazolidin-3-yl)phenyl]amide] 536751-87-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-2-oxopiperidin-1-yl)phenyl]amide] 536751-88-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-sulfamoyl-2H-pyridin-1-yl)phenyl]amide] 536751-89-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,5-dioxo-2,5-dihydropyrrol-1-yl)phenyl]amide] 536751-90-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-amino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536751-91-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-3-phenoxy-2H-pyridin-1-yl)phenyl]amide] 536751-92-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,2-dimethyl-5-oxopyrrolidin-1-yl)-2-fluorophenyl]amide] 536751-93-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536751-94-7P,
 (2R,4R)-1-[4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid tert-butyl ester 536751-95-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2,5-dioxopyrrolidin-1-yl)phenyl]amide] 536751-96-9P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-benzothiazol-2-yl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536751-97-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-amino-4,6-dimethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536751-98-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3-diethylaminomethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536751-99-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-aminomethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-00-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-methyl-5-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536752-01-9P, (2R,4R)-Acetic acid
 1-[4-[[1-[(4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridin-3-yl ester 536752-02-0P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-[3-(cyclopentanecarbonyl)amino]-2-oxo-2H-pyridin-1-yl]-2-fluorophenyl]amide] 536752-03-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(5-amino-3-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-04-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-[2-oxo-3-[(pyridin-4-yl)carbamoyl]-2H-pyridin-1-yl]phenyl]amide]

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)


RN 536749-64-1 HCAPLUS

CN 1,2,4-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-N4-methyl- (CA INDEX NAME)



RN 536749-65-2 HCAPLUS


CN 1,2,4-Pyrrolidinetricarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-N4,N4-dimethyl- (CA INDEX NAME)



RN 536749-66-3 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-

piperidinyl)phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 536749-67-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methyl- (CA INDEX NAME)




RN 536749-68-5 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(1-methylethoxy)- (CA INDEX NAME)



RN 536749-69-6 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-fluoro-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-70-9 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4,4-difluoro-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 536749-71-0 HCAPLUS

CN Proline, 1-[4-[[[1-[[[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 536749-72-1 HCAPLUS

CN Proline, 1-[4-[[[1-[[[(4-chlorophenyl)amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]phenyl]- (CA INDEX NAME)




RN 536749-88-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-89-0 HCAPLUS

CN Proline, 1-[4-[[[1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-5-oxo- (CA INDEX NAME)




RN 536749-90-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-91-4 HCAPLUS

CN 4-Imidazolidineacetic acid, 1-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2,5-dioxo- (CA INDEX NAME)




RN 536749-92-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5,5-dimethyl-2,4-dioxo-3-oxazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-93-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-pyrrolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)



RN 536749-94-7 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-oxazolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)



RN 536749-95-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-3-oxazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)

10594024




RN 536749-96-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-imidazolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-97-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-98-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2,5-dioxo-1-imidazolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536749-99-2 HCAPLUS

CN 4-Imidazolidinecarboxylic acid, 3-[4-[[[1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2-oxo- (CA INDEX NAME)




RN 536750-00-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2,4,5-trioxo-1-imidazolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-01-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-02-4 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[2-(aminomethyl)-5-oxo-1-pyrrolidinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-03-5 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[2-(aminocarbonyl)-5-oxo-1-pyrrolidinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)

10594024




RN 536750-04-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[2,2-bis(hydroxymethyl)-5-oxo-1-pyrrolidinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-05-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,3-dimethyl-2,5-dioxo-1-pyrrolidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-06-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3,3,4-trimethyl-2,5-dioxo-1-pyrrolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-07-9 HCAPLUS

CN 2,2-Pyrrolidinedicarboxylic acid, 1-[4-[[[1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-5-oxo- (CA INDEX NAME)




RN 536750-08-0 HCAPLUS

CN 1,2-Pyrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-methyl-5-oxo-1-pyrrolidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-09-1 HCAPLUS

CN 1,2-Pyrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-methyl-6-oxo-1-piperidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-10-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-hydroxy-2-oxo-1-piperidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-11-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-5-methyl-2,6-dioxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-12-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(
(tetrahydro-2-oxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy- (CA INDEX NAME)


RN 536750-13-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-
2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-14-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-piperazinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-15-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-hydroxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-16-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-17-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[6-methyl-2-oxo-4-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-18-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,6-dioxo-1-piperidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-19-3 HCAPLUS

CN 3-Piperidinecarboxylic acid, 1-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-2-oxo- (CA INDEX NAME)




RN 536750-20-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-5,5-dihydroxy-2,4,6-trioxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-21-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(tetrahydro-5,5-dihydroxy-2,4,6-trioxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-22-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)-2-fluorophenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-23-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-hydroxy-4-oxo-1-azetidiny)phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-24-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2-oxopropyl)amino]phenyl]-4-methoxy- (CA INDEX NAME)




RN 536750-25-1 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 4-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-26-2 HCAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[4-[[[1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-27-3 HCAPLUS

CN 1H-Imidazole-2-carboxylic acid, 1-[4-[[[1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-28-4 HCAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 1-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-29-5 HCAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 3-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-5-fluorophenyl]- (CA INDEX NAME)




RN 536750-30-8 HCAPLUS

CN 2-Furancarboxylic acid, 3-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-31-9 HCAPLUS

CN 2-Thiophenecarboxylic acid, 3-[4-[[[1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-32-0 HCAPLUS

CN 3-Furancarboxylic acid, 4-[4-[[[1-[[[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-33-1 HCAPLUS

CN 3-Thiophenecarboxylic acid, 4-[4-[[[1-[[[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)




RN 536750-42-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-5'-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-43-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3,5'-difluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-methoxy- (CA INDEX NAME)




RN 536750-44-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[5'-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy- (CA INDEX NAME)




RN 536750-45-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5'-difluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-methoxy- (CA INDEX NAME)




RN 536750-47-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3,5'-difluoro[1,1'-biphenyl]-4-yl]-N1-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)




RN 536750-48-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3,5'-difluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-hydroxy- (CA INDEX NAME)




RN 536750-51-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,3-dimethyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-methoxy- (CA INDEX NAME)



RN 536750-55-7 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo-1(6H)-pyridazinyl)phenyl]-4-methoxy- (CA INDEX NAME)



RN 536750-56-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-methyl-5-oxo-1,2,4-triazin-4(5H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-57-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-(3-chloro-5-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-58-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-59-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-chloro-3-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-60-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethoxy-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-61-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methoxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-62-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-oxo-3-(1H-pyrrol-1-yl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-63-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-phenyl-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-65-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1-pyrrolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-66-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-67-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dimethyl-2-oxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-68-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3,5,5-trimethyl-2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-69-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[5,5-dimethyl-3-(1-methylethyl)-2-oxo-1-imidazolidinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-70-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-2-oxo-1-imidazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-71-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5,5-dimethyl-2-oxo-1-imidazolidinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-72-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,4-dimethyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-73-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-83-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-quinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-84-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-oxo-2(3H)-isoquinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-85-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-oxo-2(1H)-isoquinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-86-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-oxo-1,2,4-triazin-4(5H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-87-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo-1(6H)-pyrimidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-88-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyrazinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-89-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyrimidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-90-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1,3,5-triazin-1(2H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-92-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-93-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-pyrazol-2-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-95-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[(2-oxo-1(2H)-pyridinyl)carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-96-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-97-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536750-99-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-00-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(methoxymethyl)-3-methyl-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-01-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[3-(methoxymethyl)-5-methyl-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-02-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5-ethyl-3-methyl-

1H-pyrazol-1-yl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-03-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[3-methyl-5-(2-methylpropyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-04-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-05-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(5-ethyl-1H-pyrazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-06-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(2-methylpropyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-07-2 HCAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-08-3 HCAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-09-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-(methoxymethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-10-7 HCAPLUS

CN 4-Oxazolecarboxylic acid, 5-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-11-8 HCAPLUS

CN 4-Oxazolecarboxylic acid, 5-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-12-9 HCAPLUS

CN 4-Oxazolecarboxylic acid, 5-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-13-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[4-(methoxymethyl)-5-oxazolyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-14-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4-ethyl-5-oxazolyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-15-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-{4-(1-methylethyl)-5-oxazolyl}phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-22-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-3-isoxazolyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-23-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(4-methyl-3-isoxazolyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

10594024


Absolute stereochemistry.



RN 536751-24-3 HCAPLUS

CN 4-Isioxazolecarboxylic acid, 3-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-25-4 HCAPLUS

CN 4-Isioxazolecarboxylic acid, 3-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-26-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(4-(methoxymethyl)-3-isoxazolyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-27-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-(1-methylethyl)-3-isoxazolyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-28-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4-cyclopropyl-3-isoxazolyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-29-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(4-cyclopropyl-3-isoxazolyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-31-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethoxy-N2-[2-methyl-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-45-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[ethyl(1-methylethyl)amino]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-46-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[ethyl(1-methylethyl)amino]carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-47-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[3-ethyl-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-48-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(3-ethyl-1-pyrrolidinyl)carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-49-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[(3R)-3-amino-1-pyrrolidinyl]carbonyl]phenyl)-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-50-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[(3R)-3-amino-1-pyrrolidinyl]carbonyl]-2-fluorophenyl)-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)-

(2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-51-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[[[(3S)-3-amino-1-pyrrolidinyl]carbonyl]phenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 536751-52-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[[[(3S)-3-amino-1-pyrrolidinyl]carbonyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-,
(2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-53-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-[[(3R)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-54-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[[(3R)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-55-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-[[(3S)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-56-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[[(3S)-3-(methylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-57-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[(3R)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-58-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[(3R)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 536751-59-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[(3S)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]phenyl]-4-methoxy-, (2R,4R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 536751-60-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[[(3S)-3-(ethylamino)-1-pyrrolidinyl]carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 536751-62-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[(2,5-dihydro-1H-pyrrol-1-yl)carbonyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-64-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[4-(1H-pyrrol-1-ylcarbonyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-65-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1H-pyrrol-1-ylcarbonyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-68-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-fluoro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-69-6 HCAPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-70-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-hydroxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-71-0 HCAPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-72-1 HCAPLUS

CN 2-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,6-dihydro-6-oxo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-73-2 HCAPLUS

CN 4-Imidazolidineacetic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]phenyl]-2,5-dioxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-74-3 HCAPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-75-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-76-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-hydroxy-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 536751-80-1 HCAPLUS

CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[4-(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,6-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-81-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,3-dimethyl-2-oxo-1-azetidiny)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-82-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(7-oxothieno[2,3-c]pyridin-6(7H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-83-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-azaspiro[4.5]dec-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-84-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-(3-benzoyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-85-6 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[3-[(acetylamino)sulfonyl]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-86-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-thiazolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-87-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1-piperidiny)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-88-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(aminosulfonyl)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-89-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-90-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-amino-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-91-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-3-phenoxy-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-92-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,2-dimethyl-5-oxo-1-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-93-6 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-94-7 HCAPLUS
 CN 3-Pyridinecarboxylic acid, 1-[4-[[[(2R,4R)-1-[[[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 536751-95-8 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2,5-dioxo-1-pyrrolidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536751-96-9 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(2-benzothiazolyl)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-97-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-(3-amino-4,6-dimethyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-98-1 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[3-[(diethylamino)methyl]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536751-99-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(aminomethyl)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-00-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-methyl-5-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-01-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-(acetyloxy)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-02-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[3-[(cyclopentylcarbonyl)amino]-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-03-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-amino-3-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-04-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-oxo-3-[(4-pyridinylamino)carbonyl]-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 536752-05-3P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3,5-dichloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-06-4P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 2-[[4-(3-amino-5-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536752-07-5P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3-cyano-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-08-6P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[[4-(3-cyano-2-oxo-5-phenyl-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-09-7P,

(2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3-ethyl-6-methyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-10-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3-cyano-4-dimethylamino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536752-11-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methyl-3-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536752-12-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-nitro-2-oxo-3-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536752-13-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(5-amino-6-oxo-6H-[3,4']bipyridinyl-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-14-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(5-chloro-3-nitro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-15-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-carbamoyl-2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536752-16-6P,
 (2R,4R)-5-Bromo-1-[4-[[1-[(4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid isobutyl ester 536752-17-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-chloro-2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)-2-fluorophenyl]amide] 1-[(4-chlorophenyl)amide] 536752-18-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-bromo-5-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-19-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(5-bromo-3-nitro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-20-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[[4-(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-nitro-2-oxo-5-trifluoromethyl-2H-pyridin-1-yl)phenyl]amide] 536752-21-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[[4-(4-chlorophenyl)amide] 2-[[2-fluoro-4-(5-methyl-3-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536752-22-4P,
 (2R,4R)-5-Chloro-1-[4-[[1-[(4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid methyl ester 536752-23-5P,
 (2R,4R)-5-Chloro-1-[4-[[1-[(4-chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]-3-fluorophenyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid 536752-24-6P, (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(4-benzoyloxy-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-25-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(4-amino-5-fluoro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-26-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-methyl-3-oxo-3H-isoquinolin-2-yl)phenyl]amide] 536752-27-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-methyl-5-nitro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536752-28-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid

2-[[4-(5-acetylamino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-29-1P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(4-amino-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-30-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(6-oxo-6H-[3,4']bipyridinyl-1-yl)phenyl]amide] 536752-31-5P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(4-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-32-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-oxo-4H-furo[3,2-c]pyridin-5-yl)phenyl]amide] 536752-33-7P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(1-oxo-1H-[2,6]naphthyridin-2-yl)phenyl]amide] 536752-34-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(5-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536752-35-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-oxo-4H-thieno[3,2-c]pyridin-5-yl)phenyl]amide] 536752-36-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(4-oxo-1,4-dihydroimidazo[4,5-c]pyridin-5-yl)phenyl]amide] 536753-22-7P,
 (2R,4R)-4-Methoxy-2-methylpyrrolidine-1,2-dicarboxylic acid
 1-[[4-(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536753-24-9P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2-dimethylaminomethylimidazol-1-yl)-2-fluorophenyl]amide] 536753-25-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[2-chloro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide]
 1-[(4-chlorophenyl)amide] 536753-27-2P,
 (2R,4R)-4-Methylpyrrolidine-1,2-dicarboxylic acid
 1-[[4-(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-28-3P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-methylaminoimidazol-1-yl)phenyl]amide] 536753-31-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(2-ethylimidazol-1-yl)-2-fluorophenyl]amide] 536753-33-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[[4-(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-isopropylimidazol-1-yl)phenyl]amide] 536753-34-1P,
 (2R,4R)-2-Ethyl-4-methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536753-35-2P,
 4-Methoxy-2-methoxymethylpyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536753-36-3P,
 2-Hydroxymethyl-4-methoxypyrrolidine-1,2-dicarboxylic acid
 1-[[4-(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536753-37-4P,
 1-[[4-(4-Chlorophenyl)carbamoyl]-2-[[2-fluoro-4-(2-oxopiperidin-1-

yl)phenyl]carbamoyle]-4-methoxypyrrolidin-2-yl]acetic acid methyl ester
 536753-38-5P, [1-[(4-Chlorophenyl)carbamoyle]-2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyle]-4-methoxypyrrolidin-2-yl]acetic acid
 536753-39-6P, 4-Hydroxymethylpyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]amide] 536753-41-0P,
 [1-[(4-Chlorophenyl)carbamoyle]-5-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyle]pyrrolidin-3-yl]acetic acid 536753-43-2P,
 [1-[(4-Chlorophenyl)carbamoyle]-5-[[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]carbamoyle]pyrrolidin-3-yl]acetic acid methyl ester
 536753-45-4P, (2R,4R)-4-Ethylpyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-47-6P,
 (2R,4R)-4-Isopropylpyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-49-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-fluoro-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-55-6P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-chloro-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536753-57-8P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 2-[[4-(3-bromo-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide]
 1-[(4-chlorophenyl)amide] 536753-61-4P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-fluoro-4-(3-iodo-2-oxo-2H-pyridin-1-yl)phenyl]amide] 536753-67-0P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[4-(3-ethyl-2-oxo-2H-pyridin-1-yl)-2-fluorophenyl]amide] 536753-69-2P,
 (2R,4R)-4-Methoxypyrrolidine-1,2-dicarboxylic acid
 1-[(4-chlorophenyl)amide] 2-[[2-methyl-4-(2-oxo-2H-pyridin-1-yl)phenyl]amide]
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)
 RN 536752-05-3 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,5-dichloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-06-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[4-(3-amino-5-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-07-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-cyano-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-08-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-cyano-2-oxo-5-phenyl-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-09-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-ethyl-6-methyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-10-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-[3-cyano-4-(dimethylamino)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-11-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-3-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-12-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[5-nitro-2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-13-3 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-amino-6-oxo[3,4'-bipyridin]-1(6H)-yl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536752-14-4 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N2-[4-(5-chloro-3-nitro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536752-15-5 HCAPLUS
 CN 1,2-Pyrrolidinededicarboxamide, N2-[4-[3-(aminocarbonyl)-2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-16-6 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-bromo-1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, 2-methylpropyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-17-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[3-chloro-2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-18-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-bromo-5-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-19-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-bromo-3-nitro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-20-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[3-nitro-2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-21-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(5-methyl-3-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-22-4 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-23-5 HCAPLUS

CN 3-Pyridinecarboxylic acid, 5-chloro-1-[4-[[[(2R,4R)-1-[[[4-chlorophenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-3-fluorophenyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-24-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-4-(phenylmethoxy)-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-25-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-amino-5-fluoro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536752-26-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-methyl-3-oxo-2(3H)-isoquinolinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-27-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-methyl-5-nitro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-28-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[5-(acetylamino)-2-oxo-1(2H)-pyridinyl]-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-29-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-amino-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-30-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(6-oxo[3,4'-bipyridin]-1(6H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-31-5 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-32-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-oxofuro[3,2-c]pyridin-5(4H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-33-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(1-oxo-2,6-naphthyridin-2(1H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536752-34-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(5-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-35-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(4-oxothieno[3,2-c]pyridin-5(4H)-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536752-36-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3,4-dihydro-4-oxo-5H-imidazo[4,5-c]pyridin-5-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-22-7 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-2-methyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-24-9 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-[2-(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-25-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N2-[2-chloro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-27-2 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methyl-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-28-3 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-(methylamino)-1H-imidazol-1-yl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536753-31-8 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(2-ethyl-1H-

imidazol-1-yl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-33-0 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-[2-(1-methylethyl)-1H-imidazol-1-yl]phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-34-1 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-2-ethyl-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 536753-35-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-methoxy-2-(methoxymethyl)- (CA INDEX NAME)




RN 536753-36-3 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-2-(hydroxymethyl)-4-methoxy- (CA INDEX NAME)




RN 536753-37-4 HCAPLUS

CN 2-Pyrrolidineacetic acid, 1-[[[(4-chlorophenyl)amino]carbonyl]-2-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-4-methoxy-, methyl ester (CA INDEX NAME)




RN 536753-38-5 HCAPLUS

CN Benzoic acid, 2-(acetyloxy)-, 1-[[[4-chlorophenyl]amino]carbonyl]-2-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl ester (CA INDEX NAME)




RN 536753-39-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]-4-(hydroxymethyl)- (CA INDEX NAME)




RN 536753-41-0 HCAPLUS

CN Benzoic acid, 2-(acetyloxy)-, 1-[[[4-chlorophenyl]amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-3-pyrrolidinyl ester
(CA INDEX NAME)



RN 536753-43-2 HCAPLUS


CN 3-Pyrrolidineacetic acid, 1-[[[4-chlorophenyl]amino]carbonyl]-5-[[[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]amino]carbonyl]-, methyl ester (CA INDEX NAME)



RN 536753-45-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-ethyl-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-47-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-(1-methylethyl)-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.




10594024

RN 536753-49-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-fluoro-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-55-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-chloro-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-57-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(3-bromo-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-N1-(4-chlorophenyl)-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-61-4 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[2-fluoro-4-(3-iodo-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-67-0 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, N1-(4-chlorophenyl)-N2-[4-(3-ethyl-2-oxo-1(2H)-pyridinyl)-2-fluorophenyl]-4-methoxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536753-69-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-4-methoxy-N2-[2-methyl-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 536747-74-7, (2R,4S)-Toluene-4-sulfonic acid

1-[(4-chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidin-3-yl ester


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536747-74-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-[[[(4-methylphenyl)sulfonyl]oxy]-, (2R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 536746-28-8P, (R)-Pyrrolidine-1,2-dicarboxylic acid
 2-[(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide]
 1-[(4-chlorophenyl)amide] 536746-32-4P,


Pyrrolidine-1,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536747-57-6P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3,5'-difluorobiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] 536747-71-4P, (2R,4R)-Toluene-4-sulfonic acid 1-[(4-chlorophenyl)carbamoyl]-5-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)carbamoyl]pyrrolidin-3-yl ester 536747-72-5P, (2R,4S)-4-Azidopyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 536748-02-4P, (2R,4R)-4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]benzoic acid methyl ester 536748-03-5P, (2R,4R)-4-[[1-[(4-Chlorophenyl)carbamoyl]-4-methoxypyrrolidine-2-carbonyl]amino]benzoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)

RN 536746-28-8 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-[[1,1-dimethylethyl]amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 536746-32-4 HCAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-[[1,1-dimethylethyl]amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 536747-57-6 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[2'-[[[(1,1-dimethylethyl)amino]sulfonyl]-3,5'-difluoro[1,1'-biphenyl]-4-yl]-4-hydroxy-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-71-4 HCAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-[[[(4-methylphenyl)sulfonyl]oxy]-, (2R,4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536747-72-5 HCAPLUS

CN 1,2-Pyrrolidinededicarboxamide, 4-azido-N1-(4-chlorophenyl)-N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-02-4 HCAPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[[[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 536748-03-5 HCAPLUS

CN Benzoic acid, 4-[[[(2R,4R)-1-[(4-chlorophenyl)amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:352811 HCAPLUS

DOCUMENT NUMBER: 129:40984

ORIGINAL REFERENCE NO.: 129:8615a,8618a

TITLE: Preparation of acylamino-substituted acylanilide derivatives as antiandrogenic agents

INVENTOR(S): Taniguchi, Nobuaki; Okada, Minoru; Kaku, Hidetaka; Shimada, Itsuro; Nozawa, Eisuke; Koutoku, Hiroshi; et al.

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----


WO 9822432 A1 19980528 WO 1997-JP4174 19971117 <--
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH,
HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG
AU 9749664 A 19980610 AU 1997-49664 19971117 <--
PRIORITY APPLN. INFO.: JP 1996-306192 A 19961118
WO 1997-JP4174 W 19971117
OTHER SOURCE(S): MARPAT 129:40984
GI



AB The title compds. [I; R1, R2 = halo, cyano, haloalkyl, NO2, etc.; R3 = H, lower alkyl; R4-R7 = H, (un)substituted lower alkyl, aralkyl, etc.; R8 = H, OH, lower alkoxy or alkyl, etc.; n = 0, 1; A1, A2 = lower alkylene; Z = acyl; X1 = O, S] are prepared I have an antiandrogenic activity and are useful as a prophylactic or therapeutic agent for prostatic cancer, prostatic hypertrophy, defeminization, hypertrichosis, bald head, acne, seborrhea and the like in which androgen is involved as an exacerbating factor. Thus, p-FC6H4SO2NHCH₂CO₂H was treated with (COCl)₂ and then reacted with 4-amino-2-trifluoromethylbenzonitrile to give I (R1 = CF₃, R2 = cyano, R3 = R5 = R8 = H, n = 0, Z = p-FC6H4SO₂, X1 = O), which showed IC₅₀ of 0.56 nM antagonist activity when tested with androgen receptor.

IT 208121-51-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylamino-substituted acylanilide derivs. as antiandrogenic agents)

RN 208121-51-1 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N1-(4-chlorophenyl)-N2-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 18 ibib abs tot

L8 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:559353 HCAPLUS

DOCUMENT NUMBER: 149:215504

TITLE: Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis

AUTHOR(S): Karnicki, Krzysztof; Leadley, Robert J., Jr.; Baxi, Sangita; Peterson, Thomas; Wysokinski, Waldemar; McBane, Robert D., II

CORPORATE SOURCE: Section of Hematology Research, Mayo Clinic, Rochester, MN, USA

SOURCE: Thrombosis and Haemostasis (2008), 99(4), 759-766

CODEN: THHADQ; ISSN: 0340-6245

PUBLISHER: Schattauer GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The objective of this study was to determine if orally-administered PD0348292, a direct specific factor Xa inhibitor, inhibits thrombosis following porcine carotid arterial injury comparably to aspirin or clopidogrel alone or in combination. We further sought to determine whether the antithrombotic efficacy in vivo could be predicted using an ex-vivo perfusion chamber. Oral treatments included: PD0348292 (0.4, 0.9, or 4.3 mg/kg); PD0348292 (0.4 mg/kg) plus aspirin (325 mg); aspirin; clopidogrel (75 mg); aspirin plus clopidogrel; or vehicle (n = 6-10/group). Aspirin and clopidogrel were administered 27 and 4 h pre-injury and PD0348292 or vehicle was administered 4 h pre-injury. Both carotid arteries were crush-injured, and thrombus was measured by detection of ¹¹¹In-platelets over 30 min. Prior to injury, the antithrombotic efficacy was assessed by ex-vivo perfusion chamber platelet deposition. PD0348292 produced dose-dependent prothrombin time (0.9- to 2.9-fold) and aPTT (1.4- to 2.5-fold) prolongations. Bleeding times were significantly prolonged in each active drug group compared to vehicle, but were not significantly different between drug groups. PD0348292 significantly inhibited arterial platelet deposition (x10⁶/cm²) at 4.3(549 ± 1,066), 0.9 (399 ± 162) and 0.4

mg/kg (531 ± 470) compared to vehicle (2,242 ± 1,443). Aspirin (992 ± 973), clopidogrel (537 ± 483), clopidogrel plus aspirin (228 ± 66) or PD0348292 plus aspirin (558 ± 317) also significantly inhibited platelet deposition, although these values were not significantly different than with any dose of PD348292. Perfusion chamber platelet deposition correlated significantly with in-vivo anti-thrombotic response. In conclusion, PD0348292 inhibited arterial thrombosis comparable to aspirin plus clopidogrel. Perfusion chamber methodol. may be useful in predicting in-vivo antithrombotic efficacy.

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:559338 HCAPLUS

DOCUMENT NUMBER: 149:172384

TITLE: Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor

AUTHOR(S): Andreotti, Felicita; Santucci, Eleonora
CORPORATE SOURCE: Department of Cardiovascular Medicine, University Hospital "A. Gemelli", Rome, Italy

SOURCE: Thrombosis and Haemostasis (2008), 99(4), 651-652
CODEN: THHADQ; ISSN: 0340-6245

PUBLISHER: Schattauer GmbH

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Role of coagulation in pathogenesis of arterial thrombosis is reviewed here. Mechanisms of actions of a variety of anticoagulants such as heparins, coumarins and fondaparinux are described. Mechanism of action of a new anticoagulant PD0348292 is described in detail.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:227623 HCAPLUS

DOCUMENT NUMBER: 149:439807

TITLE: Iliac Venous Stenting. Antithrombotic efficacy of PD0348292, an oral direct factor Xa inhibitor, compared with antiplatelet agents in pigs

AUTHOR(S): McBane, Robert D., II; Leadley, Robert J., Jr.; Baxi, Sangita M.; Karnicki, Krzysztof; Wysokinski, Waldemar
CORPORATE SOURCE: Section of Hematology Research, Mayo Clinic, Rochester, MN, USA

SOURCE: Arteriosclerosis, Thrombosis, and Vascular Biology (2008), 28(3), 413-418

CODEN: ATVBFA; ISSN: 1079-5642

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The clin. use of venous stents is increasing dramatically. Although antiplatelet agents are required for arterial stent patency, optimal thrombo-prophylaxis after venous stenting remains undefined. To address this issue, PD0348292, a direct Factor Xa inhibitor, was compared with antiplatelet therapy in a porcine venous stent model. Four hours before stent deployment, swine (n = 5 to 6 per group) received oral PD0348292 at 0.4, 0.9, 4.3 mg/kg, or 0.4 mg/kg plus aspirin (325 mg). Aspirin, clopidogrel (75 mg), aspirin plus clopidogrel, or vehicle (n=10) were

administered daily for 2 days before the procedure. Two hours after stent placement, thrombi were quantified by autologous 111In-platelet content and wts. Thrombus weight and platelet deposition were significantly reduced by PD0348292 at 0.4 (49 ± 79 mg and 110 ± 145 + 106/cm2), 0.9 (5 ± 6 mg and 107 ± 128 + 106/cm2), 4.3 mg/kg (0 ± 0 mg and 87 ± 125 + 106/cm2), and PD348292 plus aspirin (20 ± 40 mg and 157 ± 70 + 106/cm2) compared with vehicle (402 ± 226 mg; 584 ± 454 + 106/cm2). Despite prolonging bleeding times and inhibiting platelet aggregation, neither aspirin (567 ± 683 mg and 533 ± 622 + 106/cm2), clopidogrel (404 ± 349 mg and 178 ± 101 + 106/cm2), nor aspirin plus clopidogrel (247 ± 261 mg and 231 ± 266 + 106/cm2) significantly decreased stent thrombosis. PD0348292 completely inhibited thrombosis after venous stenting. Platelet accretion in these venous thrombi appear to involve pathways distinct from arachidonate metabolism or ADP P2Y12 receptor activation.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1246863 HCAPLUS

DOCUMENT NUMBER: 149:378433

TITLE: Process for the synthesis of factor Xa inhibitors

AUTHOR(S): Anon.

CORPORATE SOURCE: USA

SOURCE: IP.com Journal (2007), 7(10A), 3-4 (No.

IPCOM000158184D), 18 Sep 2007

CODEN: IJPBXX; ISSN: 1533-0001

IP.com, Inc.

PUBLISHER: Journal; Patent

DOCUMENT TYPE: English

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IP 158184D		20070918	IP 2007-158184D	20070918
			IP 2007-158184D	20070918

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 149:378433

AB The final synthesis step of a process to produce a Factor Xa inhibitor was challenging due to impurity formation. The impurities were caused by slight under- or over-charge of the reactants. Because of these impurities, charging accuracy had to exceed ± 0.1Kg in the plant in order to avoid a tedious/expensive work-up procedure. In order improve the robustness of this reaction a quenching agent, or "safener", was found that allowed excess of one of the reactants, the isocyanate, to be used. It was determined that with isopropanol present as a "safener" in the reaction mixture up to 40% molar excess of the isocyanate could be charged without any formation of the usual impurities, and none of the urethane formed from the safener ended up in the final product. Thus, the addition of isopropanol greatly expanded the range of acceptable charges and completely eliminated the need for rework of the isolated product. By avoiding the reworks, this safener has increased the yield and greatly improved the robustness of this reaction. The use of isopropanol as a safener has been successfully demonstrated on a large scale. This safener methodol. is most likely applicable to a wide variety of similar transformations.

L8 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1004082 HCAPLUS

DOCUMENT NUMBER: 147:377578

TITLE: The discovery of
(2R,4R)-n-(4-chlorophenyl)-n-(2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxyproline-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor

AUTHOR(S): Kohrt, Jeffrey T.; Bigge, Christopher F.; Bryant, John W.; Casimiro-Garcia, Agustin; Chi, Liguu; Cody, Wayne L.; Dahring, Tawny; Dudley, Danette A.; Filipski, Kevin J.; Haarer, Staci; Heemstra, Ron; Janiczek, Nancy; Narasimhan, Lakshmi; McClanahan, Thomas; Peterson, J. Thomas; Sahasrabudhe, Vaishehi; Schaum, Robert; Van Huis, Chad A.; Welch, Kathleen M.; Zhang, Erli; Leadley, Robert J.; Edmunds, Jeremy J.

CORPORATE SOURCE: Michigan Laboratories, Pfizer Global Research & Development, Ann Arbor, MI, 48105, USA


SOURCE: Chemical Biology & Drug Design (2007), 70(2), 100-112
CODEN: CBDDAL; ISSN: 1747-0277

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




I

AB Herein, we report the discovery of novel, proline-based factor Xa inhibitors containing a neutral P1 chlorophenyl pharmacophore. Through the addnl. incorporation of 1-(4-amino-3-fluoro-phenyl)-1H-pyridin-2-one 22, as a P4 pharmacophore, we discovered compound 7 (PD 0348292, I). This compound is a selective, orally bioavailable, efficacious FXa inhibitor that is currently in phase II clin. trials for the treatment and prevention of thrombotic disorders.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:809018 HCAPLUS
DOCUMENT NUMBER: 147:291356
TITLE: Structure-based drug design of pyrrolidine-1,
2-dicarboxamides as a novel series of orally
bioavailable factor Xa inhibitors
AUTHOR(S): Van Huis, Chad A.; Bigge, Christopher F.;
Casimiro-Garcia, Agustin; Cody, Wayne L.; Dudley,
Danette A.; Filipinski, Kevin J.; Heemstra, Ronald J.;
Kohrt, Jeffrey T.; Narasimhan, Lakshmi S.; Schaum,
Robert P.; Zhang, Erli; Bryant, John W.; Haarer,
Staci; Janiczek, Nancy; Leadley, Robert J., Jr.;
McClanahan, Thomas; Peterson, J. Thomas; Welch,
Kathleen M.; Edmunds, Jeremy J.
CORPORATE SOURCE: Michigan Laboratories, Pfizer Global Research &
Development, Ann Arbor, MI, 48105, USA
SOURCE: Chemical Biology & Drug Design (2007), 69(6), 444-450
CODEN: CBDDAL; ISSN: 1747-0277
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A novel series of pyrrolidine-1,2-dicarboxamides was discovered as factor Xa inhibitors using structure-based drug design. This series consisted of a neutral 4-chlorophenylurea P1, a biphenylsulfonamide P4 and a D-proline scaffold (I, IC₅₀ = 18 nM). Optimization of the initial hit resulted in an orally bioavailable, subnanomolar inhibitor of factor Xa (13, IC₅₀ = 0.38 nM), which was shown to be efficacious in a canine electrolytic model of thrombosis with minimal bleeding.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1006402 HCAPLUS
 DOCUMENT NUMBER: 145:377210
 TITLE: Preparation of polymorphic crystalline forms of
 N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-
 pyridinyl)phenyl]-4-methoxy-(2R,4R)-1,2-
 pyrrolidinedicarboxamide factor Xa inhibitor
 INVENTOR(S): Samas, Brian Matthew; Vrieze, Derek Clinton
 PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
 SOURCE: PCT Int. Appl., 31pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100565	A1	20060928	WO 2006-IB633	20060313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006226043	A1	20060928	AU 2006-226043	20060313
CA 2602550	A1	20060928	CA 2006-2602550	20060313
EP 1891044	A1	20080227	EP 2006-727345	20060313
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2006265254	A	20061005	JP 2006-81926	20060324
IN 2007DN06355	A	20070831	IN 2007-DN6355	20070816
MX 200710602	A	20080304	MX 2007-10602	20070830
KR 2007107156	A	20071106	KR 2007-721901	20070921
CN 101146792	A	20080319	CN 2006-80009365	20070921
US 20080194643	A1	20080814	US 2007-909368	20070921
PRIORITY APPLN. INFO.:			US 2005-664870P	P 20050324
			WO 2006-IB633	W 20060313

OTHER SOURCE(S): CASREACT 145:377210
 AB Polymorphic crystalline forms of N1-(4-chlorophenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-(2R,4R)-1,2-pyrrolidinedicarboxamide factor Xa inhibitor are prepared and characterized by their powder X-ray diffraction, solid-state NMR, etc., and pharmaceutical dosage forms containing it are claimed.


REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:316811 HCAPLUS

DOCUMENT NUMBER: 144:370085
 TITLE: Preparation of 1,2-pyrrolidinedicarboxamides as coagulation factor Xa inhibitors
 INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006034769	A1	20060406	WO 2005-EP9418	20050901
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
DE 102004047254	A1	20060413	DE 2004-102004047254	20040929
AU 2005289164	A1	20060406	AU 2005-289164	20050901
CA 2581732	A1	20060406	CA 2005-2581732	20050901
EP 1797071	A1	20070620	EP 2005-790356	20050901
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 101031561	A	20070905	CN 2005-80032789	20050901
JP 2008514655	T	20080508	JP 2007-533891	20050901
BR 2005015577	A	20080729	BR 2005-15577	20050901
MX 200703470	A	20070510	MX 2007-3470	20070323
KR 2007057878	A	20070607	KR 2007-707053	20070328
US 20080081814	A1	20080403	US 2007-576207	20070328
IN 2007KN01474	A	20070720	IN 2007-KN1474	20070425
PRIORITY APPLN. INFO.:			DE 2004-102004047254A	20040929
			WO 2005-EP9418	20050901

OTHER SOURCE(S): MARPAT 144:370085
 GI



AB Title compds. I [R1, R2 = H, =O, halo, etc.; R3 = H, CH2CH(OH)CH2OH, CH2CH(OH)CH2NH2, etc.; W = N, CR3 with provisos, etc.; E = together with W form a 3 to 7-membered hetero or carbocyclic ring with provisos; D = bond, double bond, etc.; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, etc.; R4 = H, A; A = alkyl with provisos; X = [C(R4)2]nCONR3[C(R4)2]n, etc.; n = 0-2; Y = alkylene, cycloalkylene, etc.; T = bond, double bond, heterocycle with provisos, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, O-acylation of hydroxypyrrolidine II [Z = H] afforded pyrrolidinedicarboxamide II [Z = CO2Et]. In coagulation factor Xa inhibition assays, pyrrolidinedicarboxamide II [Z = CO2Et] exhibited an IC50 value of 2.0x10-9 M.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:273940 HCAPLUS

DOCUMENT NUMBER: 144:331461

TITLE: Drugs containing carbonyl compounds and their use for the prophylaxis and/or therapy of thromboembolic illnesses

INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Ger. Offen., 77 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent



LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004045796	A1	20060323	DE 2004-102004045796	20040922
AU 2005287637	A1	20060330	AU 2005-287637	20050824
CA 2581172	A1	20060330	CA 2005-2581172	20050824
WO 2006032342	A2	20060330	WO 2005-EP9124	20050824
WO 2006032342	A3	20070111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1791597	A2	20070606	EP 2005-774750	20050824
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101102818	A	20080109	CN 2005-80031723	20050824
JP 2008513387	T	20080501	JP 2007-531628	20050824
BR 2005015592	A	20080729	BR 2005-15592	20050824

MX 200703175	A	20070518	MX 2007-3175	20070316
KR 2007054210	A	20070528	KR 2007-706440	20070321
US 20080003214	A1	20080103	US 2007-575711	20070321
IN 2007KN01362	A	20070720	IN 2007-KN1362	20070418
PRIORITY APPLN. INFO.:			DE 2004-10204045796A	20040922
			WO 2005-EP9124	W 20050824
OTHER SOURCE(S):	MARPAT 144:331461			
GI				



AB Use of heterocyclic carbonyl compds. I [R1, R2 = H, :O,,halogen, A, C.tplbond.CH, OR3,N(R3)2, NO2, CN, N3, CO2R3, CON(R3)2, [C(R4)2]n-Ar, [C(R4)2]n-heterocyclyl, [C(R4)2]n-cycloalkyl, OC(:O)R3, OC(:O)N(R3)2, NR3COA, NR3SO2A; R1R2 = bi- or spirocyclic 3- to 7-membered carbocycle or heterocycle (containing 0 - 3 N, O, or S); R3 = H, A, CH2C.tplbond.CH, CH2CH(OH)CH2OH, CH2CH(OH)CH2NH2, CH2CH(OH)CH2-heterocycle, [C(R4)2]n-Ar, [C(R4)2]n-heterocyclyl, [C(R4)2]n-cycloalkyl, [C(R4)2]n-CO2A, [C(R4)2]nN(R4)2; R4 = H, A; EW = 3- to 7-membered carbocycle or heterocycle (containing 0 - 3 N, O, or S); W = N, CR3, sp2-C; D = mono- or binuclear, (un)substituted aromatic carbocycle or heterocycle (containing 0 - 3 N, O, or S); G = [C(R4)2]n, [C(R4)2]n-NR3, [C(R4)2]nO, [C(R4)2]nS, [CR4:CR4]n; X = [C(R4)2]nCONR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, [C(R4)2]nNR3[C(R4)2]n, [C(R4)2]nO[C(R4)2]n, [C(R4)2]nC(:O)[C(R4)2]n, [C(R4)2]nCO2[C(R4)2]n; Y = alkylene, cycloalkylene, heterodiy, aryldiy; T = mono- or binuclear, (un)substituted aromatic carbocycle or heterocycle (containing 0 - 3 N, O, or S); A = (un)branched C1-10-alkyl (optionally containing, O, S or CH;CH in the chain and replacing 1 - 7 H with F); n = 0 - 2; o = 1 - 3], their derivs., solvates, salts and stereoisomers, for the prophylaxis and/or therapy of thromboembolic illnesses. Thus, proline derivative II was prepared from N-Boc-D-proline via amidation with 4-(4-aminophenyl)morpholin-3-one in DMF containing 1-hydroxybenzotriazole hydrate, N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride and N-methylmorpholine, N-deprotection with aqueous HCl in dioxane and carbamylation with 4-ClC6H4NCO in CH2Cl2 containing Et3N. The receptor



binding activity of II was determined [IC50 = 1.8 × 10⁻⁸ M vs. FXa; IC50 = 2.3 × 10⁻⁸ M vs. TF/FVIIa].

L8 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1075769 HCAPLUS
DOCUMENT NUMBER: 143:347450
TITLE: Synthesis of prolinyl derivatives for use in the treatment of thromboembolic diseases or tumors
INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092849	A1	20051006	WO 2005-EP2306	20050304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004014945	A1	20051013	DE 2004-102004014945	20040326
AU 2005225489	A1	20051006	AU 2005-225489	20050304
CA 2561057	A1	20051006	CA 2005-2561057	20050304
EP 1735279	A1	20061227	EP 2005-715737	20050304
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1938269	A	20070328	CN 2005-80009735	20050304
BR 2005009174	A	20070918	BR 2005-9174	20050304
JP 2007530469	T	20071101	JP 2007-504284	20050304
IN 2006KN02397	A	20070525	IN 2006-KN2397	20060824
MX 2006PA10771	A	20061215	MX 2006-PA10771	20060920
KR 2007010131	A	20070122	KR 2006-719772	20060925
US 20070135507	A1	20070614	US 2006-594024	20060925
PRIORITY APPLN. INFO.:			DE 2004-102004014945A	20040326
			WO 2005-EP2306	W 20050304

OTHER SOURCE(S): MARPAT 143:347450
GI



AB The invention relates to title compds., e.g. (I), which are inhibitors of coagulation factors Xa and VIIa and can be used for the prophylaxis and/or treatment of thromboembolic diseases and for the treatment of tumors (no data). Thus, (II) was prepared by condensation of (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-Bu ester with 4'-amino-N,N-dimethyl-[1,1'-biphenyl]-2-methanamine, followed by condensation with 4-nitrophenyl chloroformate and 4-chloroaniline, to give II (no yield). Sixteen title compds. are claimed, and formulations for administration (e.g., injections, suppositories, etc.) are given.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:564637 HCAPLUS
 DOCUMENT NUMBER: 143:97636
 TITLE: Synthesis of prolinylarylacetamides as coagulation factor Xa inhibitors for use in the prevention or treatment of thromboembolic diseases or tumors
 INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058817	A1	20050630	WO 2004-EP13509	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10358814	A1	20050721	DE 2003-10358814	20031216
AU 2004299197	A1	20050630	AU 2004-299197	20041126
CA 2549589	A1	20050630	CA 2004-2549589	20041126
EP 1697318	A1	20060906	EP 2004-820404	20041126
EP 1697318	B1	20080827		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS


CN 1894210	A	20070110	CN 2004-80037698	20041126
BR 2004017630	A	20070327	BR 2004-17630	20041126
JP 2007513988	T	20070531	JP 2006-544256	20041126
AT 406350	T	20080915	AT 2004-820404	20041126
IN 2006KN01579	A	20070504	IN 2006-KN1579	20060608
MX 2006PA06740	A	20060818	MX 2006-PA6740	20060614
US 20070185189	A1	20070809	US 2006-583094	20060615

PRIORITY APPLN. INFO.:

DE 2003-10358814	A	20031216
WO 2004-EP13509	W	20041126

OTHER SOURCE(S): MARPAT 143:97636

GI



I

AB Title compds., e.g. (I), are claimed as inhibitors of coagulation factor Xa and are claimed for use for the prophylaxis and/or therapy of thromboembolic diseases and in the treatment of tumors, as well as kits containing the compds. of interest. Thus, the title compds. were prepared, e.g., by condensation of (2R,4R)-1-(4-chlorophenylcarbamoyl)-4-hydroxyproline and N-(4-aminophenyl)-2-dimethylamino-N-Me acetamide in DMF using N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride as condensing agent. In pharmacol. testing, I had receptor affinity IC50 values of 17.0 nM and 25.0 M using FXa and TF/FVIIa receptors, resp. (no details given). Various formulations for administering the title compds. therapeutically are given.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857591 HCAPLUS

DOCUMENT NUMBER: 141:314626

TITLE: Method for the production of

pyrrolidine-1,2-dicarboxylic
acid-1-(phenyl(-amide))-2-(phenyl(-amide)) derivatives
and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid
derivatives as intermediate products

INVENTOR(S):

Mederski, Werner; Tsaklakidis, Christos; Dorsch,
Dieter; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S):

Merck Patent GmbH, Germany

SOURCE:

PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent



LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10315377	A1	20041014	DE 2003-10315377	20030403
DE 10327428	A1	20050105	DE 2003-10327428	20030618
DE 10329295	A1	20050203	DE 2003-10329295	20030630
DE 10329457	A1	20050120	DE 2003-10329457	20030701
DE 10334174	A1	20050217	DE 2003-10334174	20030726
AU 2004226280	A1	20041014	AU 2004-226280	20040309
CA 2520893	A1	20041014	CA 2004-2520893	20040309
EP 1608646	A1	20051228	EP 2004-718646	20040309
EP 1608646	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008888	A	20060411	BR 2004-8888	20040309
JP 2006522037	T	20060928	JP 2006-504602	20040309
EP 1760081	A1	20070307	EP 2006-22891	20040309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
US 20060211692	A1	20060921	US 2005-551670	20050930
IN 2005KN02182	A	20060929	IN 2005-KN2182	20051103
PRIORITY APPLN. INFO.:			DE 2003-10315377	A 20030403
			DE 2003-10327428	A 20030618
			DE 2003-10329295	A 20030630
			DE 2003-10329457	A 20030701
			DE 2003-10334174	A 20030726
			EP 2004-718646	A3 20040309
			WO 2004-EP2405	W 20040309
OTHER SOURCE(S):		CASREACT 141:314626; MARPAT 141:314626		
GI				



AB The invention relates to a method for the production of title compds., e.g. (I), and intermediate products, e.g. (II) for the production of I. Thus, cis-hydroxy-D-proline was reacted with 4-chlorophenylisocyanate in NaHCO₃ at 80° for 5 h. to give after workup 81.8% (R,R)-II. II was then reacted with 4-(3-oxo-4-morpholinyl)aniline in THF with 2-ethoxy-1(2H)-quinolinecarboxylic acid Et ester (EEDQ) as coupling agent at room temperature for 20 h to give, after workup, 69% (R,R)-I.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:857551 HCAPLUS

DOCUMENT NUMBER: 141:350179

TITLE: Preparation of azolidinedicarboxamides and related compounds as Factor Xa and Factor VIIa inhibitors
Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308
WO 2004087646	A3	20050106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG


DE 10315377	A1	20041014	DE 2003-10315377	20030403
DE 10329295	A1	20050203	DE 2003-10329295	20030630
AU 2004226278	A1	20041014	AU 2004-226278	20040308
CA 2521069	A1	20041014	CA 2004-2521069	20040308
BR 2004008420	A	20060321	BR 2004-8420	20040308
JP 2006522033	T	20060928	JP 2006-504581	20040308
EP 1720844	A2	20061115	EP 2004-718299	20040308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
RU 2337099	CZ	20081027	RU 2005-133870	20040308
IN 2005KN01684	A	20070727	IN 2005-KN1684	20050823
US 20060183739	A1	20060817	US 2005-551557	20051003

PRIORITY APPLN. INFO.:

DE 2003-10315377	A	20030403
DE 2003-10329295	A	20030630
US 2003-483897P	P	20030702
WO 2004-EP2350	W	20040308

OTHER SOURCE(S): MARPAT 141:350179

GI



I

AB R1R2(TYX)EWCOGD [R1, R2 = H, O, halo, A, ethynyl, OR3, N(R3)2, NO2, cyano, N3, CO2R3, CON(R3)2, etc.; R3 = H, A, HC.tpiibond.CCH2, MeC.tpiibond.CCH2, CH2CH(OH)CH2OH, etc.; R4 = H, A; W = N, C, CR3; E = atoms to form a 3-7 membered (heterocyclic) ring optionally containing a double bond; D = mono- or dinuclear (substituted) (hetero)aryl; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS, etc.; n = 0-2; X = [C(R4)2]nCO[C(R4)2]n, [C(R4)2]nNR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, heterocyclylene, arenediyl; T = substituted mono- or dinuclear carbocyclyl, heterocyclyl; A = (fluoro-substituted) alkyl optionally interrupted by O, S, CH:CH], were prepared Thus, title compound (I) [preparation from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate given] bound to Factor Xa receptors with IC50 = 1.8×10^{-8} M.

L8 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:841766 HCAPLUS

DOCUMENT NUMBER: 141:332202

TITLE: Preparation of azolidinecarboxamides as antithrombotics and anticancer drugs.

INVENTOR(S): Tsaklakidis, Christos; Dorsch, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
 SOURCE: Ger. Offen., 47 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10315377	A1	20041014	DE 2003-10315377	20030403
AU 2004226278	A1	20041014	AU 2004-226278	20040308
CA 2521069	A1	20041014	CA 2004-2521069	20040308
WO 2004087646	A2	20041014	WO 2004-EP2350	20040308
WO 2004087646	A3	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2004008420	A	20060321	BR 2004-8420	20040308
CN 1771237	A	20060510	CN 2004-80009354	20040308
JP 2006522033	T	20060928	JP 2006-504581	20040308
EP 1720844	A2	20061115	EP 2004-718299	20040308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV				
RU 2337099	C2	20081027	RU 2005-133870	20040308
AU 2004226280	A1	20041014	AU 2004-226280	20040309
AU 2004226281	A1	20041014	AU 2004-226281	20040309
CA 2520893	A1	20041014	CA 2004-2520893	20040309
CA 2520894	A1	20041014	CA 2004-2520894	20040309
WO 2004087695	A1	20041014	WO 2004-EP2405	20040309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004087696	A1	20041014	WO 2004-EP2407	20040309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


EP 1608645 A1 20051228 EP 2004-718641 20040309
 EP 1608645 B1 20070502
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

EP 1608646 A1 20051228 EP 2004-718646 20040309
 EP 1608646 B1 20070711
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

BR 2004008444 A 20060404 BR 2004-8444 20040309
 BR 2004008888 A 20060411 BR 2004-8888 20040309
 CN 1771248 A 20060510 CN 2004-80009374 20040309
 CN 1771249 A 20060510 CN 2004-80009463 20040309
 JP 2006522037 T 20060928 JP 2006-504602 20040309
 JP 2006522038 T 20060928 JP 2006-504604 20040309
 AT 361296 T 20070515 AT 2004-718641 20040309
 AT 366732 T 20070815 AT 2004-718646 20040309
 ES 2285444 T3 20071116 ES 2004-718641 20040309
 ES 2287708 T3 20071216 ES 2004-718646 20040309
 IN 2005KN01684 A 20070727 IN 2005-KN1684 20050823
 US 20060211692 A1 20060921 US 2005-551670 20050930
 US 20060183739 A1 20060817 US 2005-551557 20051003
 US 20060183742 A1 20060817 US 2005-551559 20051003
 IN 2005KN02182 A 20060929 IN 2005-KN2182 20051103
 IN 2005KN02183 A 20070323 IN 2005-KN2183 20051103

PRIORITY APPLN. INFO.:
 DE 2003-10315377 A 20030403
 DE 2003-10327428 A 20030618
 DE 2003-10329295 A 20030630
 DE 2003-10329457 A 20030701
 US 2003-483897P P 20030702
 DE 2003-10334174 A 20030726
 DE 2003-10336570 A 20030808
 WO 2004-EP2350 W 20040308
 WO 2004-EP2405 W 20040309
 WO 2004-EP2407 W 20040309

OTHER SOURCE(S): MARPAT 141:332202
 GI



AB R1R2(TYX)EWCOGD [R1, R2 = H, O, halo, A, ethynyl, OR3, NO2, cyano, N3, CO2R3, CON(R)2, NR3COA, NR3SO2A, etc.; R1R2 = toms to form a bicyclic or spirocyclic (heterocyclic) ring; R3 = H, A, etc.; R4 = H, A; W = N, CR3, C; E = atoms to form a 3-7 membered (double bond containing) (heterocyclic) ring with W; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS; X =

[C(R4)2]nCONR3[C(R4)2]n, [C(R4)2]nON[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, (substituted) heterocyclylene, arylene; T = mono- or bicyclic substituted (unsatd.) (hetero)cyclyl; A = (fluoro-substituted) alkylene optionally interrupted by O, S, CH:CH; n = 0-2], were prepared. Thus, title compound (I) (prepared from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate), bound to Factor Xa receptors with IC50 = 1.8 + 10-8 M.

L8 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:799558 HCAPLUS

DOCUMENT NUMBER: 141:296012

TITLE: Preparation of factor Xa- and thrombin-inhibiting substituted benzamidines and sulfonylbenzamidines as potential anticoagulants

INVENTOR(S): Pinto, Donald J.; Qiao, Jennifer X.; Gangor, Timur; Lam, Patrick Y. S.; Li, Yun-long

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 279 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083174	A2	20040930	WO 2004-US8033	20040317
WO 2004083174	A3	20041125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040209863	A1	20041021	US 2004-801518	20040316
US 7122557	B2	20061017		
EP 1603562	A2	20051214	EP 2004-757516	20040317
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			US 2003-455709P	P 20030318
			US 2004-801518	A 20040316
			WO 2004-US8033	W 20040317

OTHER SOURCE(S): MARPAT 141:296012

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. P4-M-M4 (I) [M = (un)substituted 3-10 membered carbocyclic or a 4-10 membered heterocyclic ring containing 1-3 O, N, or S atoms, alone or

fused to an (un)substituted 5-7 membered carbocycle or heterocycle; P4 = Z-A-B; M4 = G-G1; A = (un)substituted 3-10 membered carbocyclic or 5-12 membered heterocyclic ring; B = (un)substituted amidino, guanidino, iminomethyl; G = five or six-membered carbocycle or heterocycle fused to a benzene, pyridine, pyrimidine, pyrazine, or pyridazine ring; G1 = bond, (un)substituted alkyl, alkenyl, alkynyl; Z = (un)substituted alkylene], such as tetrahydropyrazolo[3,4-c]pyridinone II or (pyridinylaminocarbonylphenylaminocarbonyl)benzamide III are prepared as inhibitors of Factor Xa and thrombin for use as anticoagulants. Deprotonation of 2-amino-4-chloropyridine and addition to 5-chloroisatoic anhydride yields N-(5-chloro-2-pyridinyl) 2-amino-5-chlorobenzamide (IV). Acid-mediated addition of dimethylamine to the nitrile of Me 4-cyanobenzoate, mesylation of the amidine nitrogen, and base-mediated hydrolysis of the ester yields 4-(N,N-dimethyl-N'-methylsulfonylamidino)benzoic acid (V). Coupling of IV and V mediated by BOP yields III. Some compds. of the invention inhibit human factor Xa with Ki values of ≤ 10 μ M; in addition, some of the invention compds. inhibit thrombin in vitro. (no data).

L8 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:434528 HCAPLUS

DOCUMENT NUMBER: 139:6763

TITLE: Preparation of pyrrolidinedicarboxamides and related compounds as inhibitors of factor Xa useful for thrombotic disorders

INVENTOR(S): Bigge, Christopher Franklin; Dudley, Danette Andrea; Edmunds, Jeremy John; Van Huis, Chad Alan; Casimiro-Garcia, Agustín; Filipski, Kevin James; Kohrt, Jeffrey Thomas

PATENT ASSIGNEE(S): Warner-Lambert Company L.L.C., USA

SOURCE: PCT Int. Appl., 389 pp.

CODEN: P1XXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045912	A1	20030605	WO 2002-IB4757	20021114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 20030162787	A1	20030828	US 2002-278643	20021023
US 7030141	B2	20060418		
CA 2468715	A1	20030605	CA 2002-2468715	20021114
AU 2002365313	A1	20030610	AU 2002-365313	20021114
AU 2002365313	B2	20080306		
BR 2002014519	A	20041013	BR 2002-14519	20021114
EP 1465864	A1	20041013	EP 2002-803885	20021114
EP 1465864	B1	20060315		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

CN 1582274	A	20050216	CN 2002-823837	20021114
HU 2004002529	A2	20050329	HU 2004-2529	20021114
JP 2005515985	T	20050602	JP 2003-547364	20021114
AT 320414	T	20060415	AT 2002-803885	20021114
EP 1671949	A2	20060621	EP 2006-110738	20021114
EP 1671949	A3	20060719		
EP 1671949	B1	20080723		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK


PT 1465864	T	20060630	PT 2002-803885	20021114
ES 2259113	T3	20060916	ES 2002-803885	20021114
NZ 532384	A	20061027	NZ 2002-532384	20021114
AP 1744	A	20070630	AP 2004-3035	20021114
AT 402148	T	20080815	AT 2006-110738	20021114
MX 2004PA03606	A	20040727	MX 2004-PA3606	20040416
ZA 2004004085	A	20050905	ZA 2004-4085	20040525
NO 2004002270	A	20040601	NO 2004-2270	20040601
US 20050267118	A1	20051201	US 2004-17598	20041220
US 7407972	B2	20080805		
US 20050250815	A1	20051110	US 2005-108582	20050418
US 7407974	B2	20080805		
US 20060264626	A1	20061123	US 2006-461859	20060802

PRIORITY APPLN. INFO.:

US 2001-334168P	P	20011129
US 2002-384895P	P	20020531
US 2002-278643	A3	20021023
EP 2002-803885	A3	20021114
WO 2002-IB33416	A	20021114
WO 2002-IB4757	W	20021114
US 2004-17598	A3	20041220

OTHER SOURCE(S): MARPAT 139:6763

GI



AB The present invention provides pyrrolidinedicarboxamides and related compds. (shown as I; variables defined below; e.g. (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide]) and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compds. comprising ≥ 1 compds. I, processes for preparing I, and intermediates useful for preparing I. IC50 values for inhibition of factor Xa are tabulated for >170 examples of I. About 180 example preps. of I are included. For example, (R)-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chlorophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] was prepared in 4 steps starting from Fmoc-D-Pro, SOC12, and 4-bromo-2-fluoroaniline and involving intermediates (R)-2-[(4-bromo-2-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester, (R)-pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide, and

(R)-pyrrolidine-1,2-dicarboxylic acid 2-[(2-tert-butylsulfamoyl-3-fluorobiphenyl-4-yl)amide] 1-[(4-chlorophenyl)amide] with yields of 99, 70, 66 and 76%, resp. Four pharmaceutical formulations are described. For I: A is (un)substituted aryl or (un)substituted monocyclic heteroaryl; B is -NHC(O)(C1-C6)alkyl, -NHC(O)(C3-C7)cycloalkyl, -NHC(O)O(C1-C6)alkyl, -C(O)R1, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4-C7)cycloalkenyl, unsatd. (C4-C7)heterocyclo, aryl, or heteroaryl, any of which may be (un)substituted by halo, (C1-C6)alkyl, or halo(C1-C6)alkyl, O(C1-C6), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido. C is Ph or heteroaryl, wherein Ph or heteroaryl is (un)substituted with ≥ 1 substituents = aryl, heteroaryl, halogen, hydroxy, -CO2R2, -COR2, -CONR2R2', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; G is H, halo, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, -CH2O(C1-C6)alkyl, -CH2CO2(C1-C6)alkyl, -CH2NR2R2', or -CH2C(O)NH(C1-C6)alkyl. W1 is a saturated or unsatd., (un)substituted hydrocarbon chain or hydrocarbon-heteroatom chain having 2-6 atoms, wherein W1 connects the N atom at position 1 to the C atom at position 2 to form a four to eight membered ring; R1 is (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4-C7)cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -NR3R4; R2 and R2' are each independently H or (C1-C6)alkyl; and R3 and R4 are each independently H, (C1-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxy carbonyl, aralkoxy carbonyl, -SO2alkyl, or joined together to form a saturated or unsatd. 3 to 7 membered ring.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:352811 HCAPLUS

DOCUMENT NUMBER: 129:40984

ORIGINAL REFERENCE NO.: 129:8615a,8618a

TITLE: Preparation of acylamino-substituted acylanilide derivatives as antiandrogenic agents
INVENTOR(S): Taniguchi, Nobuaki; Okada, Minoru; Kaku, Hidetaka; Shimada, Itsuro; Nozawa, Eisuke; Koutoku, Hiroshi; et al.

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9822432	A1	19980528	WO 1997-JP4174	19971117
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9749664	A	19980610	AU 1997-49664	19971117
PRIORITY APPLN. INFO.:			JP 1996-306192	A 19961118

OTHER SOURCE(S):

MARPAT 129:40984

GI



AB The title compds. [I; R1, R2 = halo, cyano, haloalkyl, NO2, etc.; R3 = H, lower alkyl; R4-R7 = H, (un)substituted lower alkyl, aralkyl, etc.; R8 = H, OH, lower alkoxy or alkyl, etc.; n = 0, 1; A1, A2 = lower alkylene; Z = acyl; X1 = O, S] are prepared I have an antiandrogenic activity and are useful as a prophylactic or therapeutic agent for prostatic cancer, prostatic hypertrophy, defeminization, hypertrichosis, bald head, acne, seborrhea and the like in which androgen is involved as an exacerbating factor. Thus, p-FC6H4SO2NHCH₂EtCO₂H was treated with (COCl)₂ and then reacted with 4-amino-2-trifluoromethylbenzonitrile to give I (R1 = CF₃, R2 = cyano, R3 = R5 = R8 = H, n = 0, Z = p-FC6H4SO₂, X1 = O), which showed IC₅₀ of 0.56 nM antagonist activity when tested with androgen receptor.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

119.83

478.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-18.40

-18.40

STN INTERNATIONAL LOGOFF AT 09:20:55 ON 14 NOV 2008